<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prednisone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prednisone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prednisone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10992" href="/d/html/10992.html" rel="external">see "Prednisone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12725" href="/d/html/12725.html" rel="external">see "Prednisone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F213098"><span class="drugH1">Brand Names: US</span>
<ul>
<li>predniSONE Intensol;</li>
<li>Rayos</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868014"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-PredniSONE;</li>
<li>TEVA-PredniSONE;</li>
<li>Winpred</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F213145"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Corticosteroid, Systemic</li></ul></div>
<div class="block doa drugH1Div" id="F213103"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize glucocorticoid dosing and use the minimum effective dose/duration. Evidence to support an optimal dose and duration is lacking for most indications; recommendations provided are general guidelines only.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> HPA-axis suppression is likely in any adult receiving &gt;20 mg/day (daytime dosing) or ≥5 mg per 24 hours (evening or night dosing) for &gt;2 weeks or with Cushingoid appearance (although HPA suppression may occur with lower doses or briefer exposure in some patients); do not abruptly discontinue treatment; dose tapering may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594318','lexi-content-ref-Furst.2019b','lexi-content-ref-27105755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594318','lexi-content-ref-Furst.2019b','lexi-content-ref-27105755'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 to 60 mg/day given in a single daily dose or in 2 to 4 divided doses; <i>Low dose:</i> 2.5 to 10 mg/day; <i>High dose:</i> 1 to 1.5 mg/<b>kg</b>/day (usually not to exceed 80 to 100 mg/day).</p>
<p style="text-indent:-2em;margin-left:6em;">The following dose taper example is from the commercially available tapered-dosage product:</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: Administer 30 mg on day 1 as 10 mg at breakfast, 5 mg at lunch, 5 mg at dinner, and 10 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2: Administer 25 mg on day 2 as 5 mg at breakfast, 5 mg at lunch, 5 mg at dinner, and 10 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 3: Administer 20 mg on day 3 as 5 mg at breakfast, 5 mg at lunch, 5 mg at dinner, and 5 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 4: Administer 15 mg on day 4 as 5 mg at breakfast, 5 mg at lunch, and 5 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 5: Administer 10 mg on day 5 as 5 mg at breakfast and 5 mg at bedtime.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 6: Administer 5 mg on day 6 as 5 mg at breakfast.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc00fdd1-dcbe-4bc8-aeed-8fa0399f4f39">Adrenal insufficiency, primary chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal insufficiency, primary chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In general, hydrocortisone is preferred. Use in conjunction with fludrocortisone. Dose is based on prednisolone equivalency.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Chronic maintenance dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dosage range: 2.5 to 7.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Nieman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Nieman.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Stress dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients who are unable to tolerate oral medication (eg, due to vomiting or diarrhea), are in active labor, or are under moderate to major surgical stress may require parenteral corticosteroid therapy (preferably with hydrocortisone) to prevent adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with febrile illness: </i>Double the chronic maintenance dose until recovery for fever 38°C (100.4°F) to 39°C (102.2°F) or triple the chronic maintenance dose until recovery for fever &gt;39°C (102.2°F), then return to baseline dose within 1 to 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Minor surgical stress (eg, hernia repair, procedures with local anesthetic):</i> Continue chronic maintenance dose (no additional supplementation needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.2020','lexi-content-ref-8161268']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11779267','lexi-content-ref-Hamrahian.2020','lexi-content-ref-8161268'])">Ref</a></span>); may give an additional 5 mg (equivalent to ~20 mg hydrocortisone) postoperatively if signs or symptoms of adrenal insufficiency are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25288693','lexi-content-ref-24330030']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25288693','lexi-content-ref-24330030'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="62ac398e-8662-4f04-853e-eaeb0e587d10">Alcoholic hepatitis, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcoholic hepatitis, severe (Maddrey Discriminant Function [MDF] score ≥32) (off-label use):</b>
<b>Oral:</b> 40 mg daily for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35333779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35333779'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0c5cf88b-31e2-4e53-a82c-cf4650d1d56c">Angioedema and/or new-onset urticaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema (acute allergic) and/or new-onset urticaria: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For moderate to severe symptoms without signs of anaphylaxis. Use epinephrine if anaphylaxis symptoms (eg, risk of airway or cardiovascular compromise) are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Zuraw.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Zuraw.2021'])">Ref</a></span>). In patients with new-onset urticaria, reserve use for those with significant angioedema or with symptoms that are unresponsive to antihistamines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Asero.2021','lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Asero.2021','lexi-content-ref-34536239'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> The optimal dosing strategy has not been defined; an example regimen is 20 to 60 mg daily initially, followed by a taper over 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Asero.2021','lexi-content-ref-34536239','lexi-content-ref-Zuraw.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Asero.2021','lexi-content-ref-34536239','lexi-content-ref-Zuraw.2021'])">Ref</a></span>). The total treatment duration should not exceed 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34536239'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For moderate to severe exacerbations or in patients who do not respond promptly and completely to short-acting beta agonists; administer within 1 hour of presentation to emergency department (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 to 60 mg daily for 5 to 7 days; administer in 1 or 2 divided doses. If symptoms do not resolve and peak expiratory flow is not at least 70% of personal best, then longer treatment may be required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2','lexi-content-ref-NAEPP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01d3e8c6-1ec1-4614-aae2-225baffa4c00">Bell palsy, new onset</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bell palsy, new onset (off-label use):</b>
<b>Oral:</b> 60 to 80 mg daily for 5 to 7 days; administer in 1 or 2 divided doses; may be followed by a 5-day taper. Treatment should begin within 72 hours of onset of symptoms; a concomitant antiviral agent may be indicated in select patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8246650','lexi-content-ref-24934895','lexi-content-ref-18849193','lexi-content-ref-24189771','lexi-content-ref-Ronthal.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8246650','lexi-content-ref-24934895','lexi-content-ref-18849193','lexi-content-ref-24189771','lexi-content-ref-Ronthal.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="144bfda0-cd07-4b30-a02a-f08025a0fc36">Bullous pemphigoid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bullous pemphigoid (off-label use):</b>
<b>Oral:</b> Initial: 0.5 mg/kg/day. May begin gradual taper over 4 to 6 months when disease is controlled (eg, no new lesions or pruritic symptoms for ≥2 weeks and most established lesions have healed). May discontinue therapy if complete remission maintained for at least 3 to 6 months on doses ≤0.1 mg/kg/day (usual total duration: 9 to 12 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35766904','lexi-content-ref-11821508','lexi-content-ref-20927731','lexi-content-ref-Murrell.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35766904','lexi-content-ref-11821508','lexi-content-ref-20927731','lexi-content-ref-Murrell.2023'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inadequate initial control: </i>In patients who do not achieve disease control within 1 to 3 weeks of initial therapy, may increase to 0.75 mg/kg/day; may also consider addition of other agents (eg, topical corticosteroids, immunosuppressants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35766904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35766904'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Disease recurrence</i>: Return to the preceding lowest effective treatment dose; if not effective, return to initial effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35766904','lexi-content-ref-Murrell.2023']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35766904','lexi-content-ref-Murrell.2023'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients with severe but not life-threatening exacerbations, oral regimens are recommended. In patients who cannot tolerate oral therapy (eg, shock, mechanically ventilated), use IV methylprednisolone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 to 60 mg once daily for 5 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-Stoller.1'])">Ref</a></span>). <b>Note:</b> The optimal dose has not been established. If patient improves with therapy, may discontinue without taper. If patient does not improve, a longer duration of therapy may be indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="894e2a7e-3fff-4cb6-8ddb-f11aa30fb548">COVID-19, hospitalized patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>COVID-19, hospitalized patients (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Prednisone is recommended for treatment of COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support when dexamethasone is not available or there are specific indications for prednisone. Dosing is extrapolated from a study that used dexamethasone; the equivalent dose of prednisone (or other glucocorticoid) may be substituted if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.2022','lexi-content-ref-NIH.2022','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.2022','lexi-content-ref-NIH.2022','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg once daily or 20 mg twice daily for up to 10 days (or until discharge, if sooner) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bhimraj.2022','lexi-content-ref-NIH.2022','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bhimraj.2022','lexi-content-ref-NIH.2022','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy (off-label use): Oral:</b> 0.75 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937','lexi-content-ref-21753160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937','lexi-content-ref-21753160'])">Ref</a></span>). Some experts use a maximum dose of 40 mg/day due to potential for greater adverse effects and decreased benefit at higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Darras.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Darras.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In patients who experience intolerable adverse effects, may decrease the dose by 25% to 33% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29395989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29395989'])">Ref</a></span>). If adverse effects persist, continue to gradually taper to as low as 0.3 mg/kg/day, which may provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937','lexi-content-ref-Darras.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937','lexi-content-ref-Darras.2020'])">Ref</a></span>). Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses &gt;0.75 mg/kg/day provide greater efficacy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937','lexi-content-ref-27149418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937','lexi-content-ref-27149418'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53a56999-6b4a-4e0e-9353-5f99cc832005">Focal segmental glomerulosclerosis, primary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Focal segmental glomerulosclerosis, primary (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Initial therapy for patients with nephrotic syndrome (eg, proteinuria &gt;3.5 g/day and serum albumin &lt;3.5 g/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 mg/kg (maximum dose: 60 to 80 mg/day) once daily <b>or</b> 2 mg/kg (maximum dose: 120 mg) every other day; duration of therapy depends on clinical response and tapering schedule can vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.2022','lexi-content-ref-34556256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.2022','lexi-content-ref-34556256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd1bdfb0-f04d-4bd1-896f-dcb090cb438a">Giant cell arteritis, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giant cell arteritis, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>To reduce the risk of visual loss, start treatment <b>immediately</b> once diagnosis is highly suspected (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20371504','lexi-content-ref-17504884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20371504','lexi-content-ref-17504884'])">Ref</a></span>). In patients presenting <b>with </b>threatened vision loss, pulse IV methylprednisolone is suggested as initial therapy prior to an oral glucocorticoid (eg, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235884']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235884'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 to 60 mg once daily for 2 to 4 weeks; if reversible symptoms persist or worsen, may increase dose up to a maximum dose of 80 mg once daily until symptomatic control is achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20371504','lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20371504','lexi-content-ref-Salvarani.1'])">Ref</a></span>). Alternatively, may initiate at 1 mg/kg once daily (maximum: 80 mg/day), particularly in patients with signs of ischemic organ damage (eg, vision loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235884','lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235884','lexi-content-ref-Salvarani.1'])">Ref</a></span>). Once signs/symptoms have declined and laboratory values have returned to normal or near normal, begin to taper until discontinuation over the next 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20371504','lexi-content-ref-Salvarani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20371504','lexi-content-ref-Salvarani.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a81184b-235e-4be1-8cc9-23a33b10cc65">Gout, treatment, acute flares</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gout, treatment, acute flares:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use in patients with known or suspected septic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gaffo.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gaffo.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 30 to 40 mg/day given once daily or in 2 divided doses until symptom improvement (usually 2 to 5 days), then taper gradually as tolerated (typically over 7 to 10 days); a slower taper (eg, over 14 to 21 days) may be required, particularly in patients with multiple recent flares (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27802508','lexi-content-ref-23024029','lexi-content-ref-27457514','lexi-content-ref-Gaffo.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27802508','lexi-content-ref-23024029','lexi-content-ref-27457514','lexi-content-ref-Gaffo.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba4cbc5f-890b-41ec-b2b1-c3687f7e3787">Graft-versus-host disease, acute, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute, treatment (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For grade II or higher acute graft-versus-host disease. An optimal regimen has not been identified; refer to institutional protocols as variations exist. Treatment is dependent on the severity and the rate of progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22510384','lexi-content-ref-23892326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22510384','lexi-content-ref-23892326'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2 to 2.5 mg/kg/day in divided doses; dose may vary based on organ involvement and severity. Continue for several weeks then taper over several months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22510384','lexi-content-ref-Zeiser.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22510384','lexi-content-ref-Zeiser.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72c5a8aa-8a91-445e-bf5b-2a2891c880bd">Hepatitis, autoimmune</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis, autoimmune (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Approach to treatment should be patient specific and guided by response to treatment. Monotherapy induction regimen included below; other induction regimens (eg, combination therapy with a glucocorticoid-sparing agent) may be used in select patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31863477','lexi-content-ref-26341719','lexi-content-ref-Heneghan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31863477','lexi-content-ref-26341719','lexi-content-ref-Heneghan.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction:</i> Initial: <b>Oral:</b> 40 to 60 mg once daily for 1 week or until biochemical remission achieved, followed by a taper (eg, reduce daily dose by 5 to 10 mg at weekly intervals) based on symptoms and laboratory values to 20 mg once daily or a dose sufficient for maintenance of remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31863477','lexi-content-ref-Heneghan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31863477','lexi-content-ref-Heneghan.2022'])">Ref</a></span>). Some experts initiate therapy at 20 to 30 mg once daily depending on severity of disease and tolerance to glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Heneghan.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Heneghan.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance:</i> Further taper dose to one that maintains remission (eg, taper the dose by 2.5 to 5 mg every 2 to 4 weeks to reach 5 to 10 mg/day). Specific maintenance approach will depend on patient response to initial treatment and tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31863477']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31863477'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0e8695a-ab23-4579-8a2a-e35dd8656c8d">IgA nephropathy, primary, nonvariant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>IgA nephropathy, primary, nonvariant (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May consider for use in selected patients at high risk of chronic kidney disease progression (eg, proteinuria ≥0.75 to 1 g/day) despite 3 to 6 months of optimized doses of nonimmunosuppressive therapies (eg, renin-angiotensin system inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.2023','lexi-content-ref-34556256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.2023','lexi-content-ref-34556256'])">Ref</a></span>). The optimal dose has not been established and may vary based on institutional protocols and patient-specific factors; an example regimen (based on an equivalent dose of methylprednisolone) is provided below.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 0.5 mg/kg once daily for 2 months (maximum dose: 40 mg/day). Taper daily dose every month over an additional 4 to 7 months. <b>Note:</b> Antimicrobial prophylaxis for Pneumocystis pneumonia was also prescribed for the first 12 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35579642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35579642'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="58acdf8a-6a05-45e7-a020-bd4c6e72f2ed">Immune thrombocytopenia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Goal of therapy is to provide a safe platelet count to prevent clinically important bleeding rather than normalization of the platelet count. For patients with severe bleeding, a pulse of dexamethasone or methylprednisolone is recommended; due to the short-term response associated with methylprednisolone, a prednisone taper may be required following pulse doses of methylprednisolone. For minor bleeding, prednisone is an appropriate initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.2022','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.2022','lexi-content-ref-31770441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>I</i>
<i>nitial therapy: </i>
<b>Oral:</b> 1 mg/kg/day (range: 0.5 to 2 mg/kg/day; maximum: 80 mg/day) for 1 to 3 weeks, followed by a gradual taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnold.2022','lexi-content-ref-31794604','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnold.2022','lexi-content-ref-31794604','lexi-content-ref-31770441'])">Ref</a></span>). Total duration of therapy should not exceed 6 weeks; if there is no response within 2 weeks, taper over 1 week and discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794604','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794604','lexi-content-ref-31770441'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Pregnancy associated:</b></i>
<b>Oral:</b> Initial: 10 to 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801473']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801473'])">Ref</a></span>). Adjust to the minimum effective dose to achieve response; generally, continue for at least 21 days, then taper to the minimum effective dose required to maintain platelet count to prevent major bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801473','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801473','lexi-content-ref-31770441'])">Ref</a></span>) <b>or </b>1 mg/kg/day for 2 weeks, followed by a gradual taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-George.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-George.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Fetal alloimmune thrombocytopenia (maternal administration):</i></b>
<b>Oral:</b> 0.5 to 1 mg/kg/day. Dose is dependent upon gestational age and risk of fetal/neonatal intracranial hemorrhage and is administered in addition to immune globulin IV (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30801473','lexi-content-ref-22015886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30801473','lexi-content-ref-22015886'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d1b7ab81-2e45-4176-819b-c990267698da">Immune-mediated adverse reactions associated with immune checkpoint inhibitor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune-mediated adverse reactions associated with immune checkpoint inhibitor therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consider withholding immune checkpoint inhibitor (ICI) therapy for most grade 2 toxicities, withhold the ICI for grade 3 toxicity and permanently discontinue for most grade 4 toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Refer to each ICI monograph for specific dosage modification and management details.</p>
<p style="text-indent:-2em;margin-left:4em;">General prednisone dosing recommendations:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2 toxicity (if ICI is withheld):</i>
<b>Oral: </b>Consider 0.5 to 1 mg/kg/day until improvement to ≤ grade 1, then taper prednisone over at least 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immune-mediated hepatitis, </i>
<i>grade 2: </i>Withhold ICI. If no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or higher toxicity:</i>
<b> Oral: </b>1 to 2 mg/kg/day until improvement to ≤ grade 1, then taper prednisone over 4 to 6 weeks; consider other systemic immunosuppressants if symptoms do not improve with 48 to 72 hours of corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>ICI-induced hypophysitis:</i> In patients without adrenal insufficiency, high doses of corticosteroids (short-term courses [as above]) may only be necessary in cases of pituitary enlargement that could lead to chiasma compression or with severe compressive symptoms (eg, headache, double vision) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36149449','lexi-content-ref-36884258']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36149449','lexi-content-ref-36884258'])">Ref</a></span>). Higher corticosteroid doses may be associated with worse clinical outcomes in patients with ICI-induced hypophysitis and are otherwise not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36149449','lexi-content-ref-29975414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36149449','lexi-content-ref-29975414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Immune-mediated hepatitis, grade 3 or 4: </i>Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with lower corticosteroid doses (eg, methylprednisolone 1 mg/kg/day or equivalent) demonstrated similar time to ALT normalization (compared with higher corticosteroid doses), while reducing the potential for corticosteroid-related complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34709662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34709662'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prednisone </i>
<i>tapering (general recommendations): </i>
<b>Oral: </b>Reduce prednisone dose by 10 mg every 3 to 7 days (as immune-mediated adverse reaction allows) until the dose is 10 mg/day, then reduce dose by 5 mg every 3 to 7 days. Consider more prolonged tapering for patients who received several weeks of corticosteroids; longer tapering may be required for complete resolution or to avoid adverse reaction rebound. For grade 3 or 4 immune-mediated hepatitis, steroid taper may be attempted at ~4 to 6 weeks (after improvement to ≤ grade 1) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9117d6e1-33df-4646-bf4f-7e3751815245">Inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inflammatory bowel disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Crohn disease (moderate to severe or select patients with mild disease), induction:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: Not</b> for long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 40 to 60 mg once daily for 7 to 14 days, followed by a taper of up to 3 months (eg, reduce dose by 5 mg/day at weekly intervals until 20 mg/day is reached, then further reduce by 2.5 to 5 mg/day at weekly intervals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>). Tapering regimens vary; some experts recommend a more rapid taper with a goal of discontinuing therapy within 1 to 2 months; if symptoms return, may resume therapy and taper more slowly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Regueiro.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Regueiro.2022'])">Ref</a></span>). Steroid-sparing agents (eg, biologic agents, immunomodulators) should be introduced with a goal of discontinuing corticosteroid therapy as soon as possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Ulcerative colitis (moderate to severe), induction:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: Not</b> for long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 40 to 60 mg/day in 1 to 2 divided doses. Clinical improvement is expected within 7 days; pace of tapering (usually over 1 to 3 months) should be guided by symptoms, cumulative steroid exposure, and onset of action of additional therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30840605','lexi-content-ref-alHashash.2021','lexi-content-ref-Cohen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30840605','lexi-content-ref-alHashash.2021','lexi-content-ref-Cohen.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b6caea-ebbf-4c1e-93f2-543c99fc4e9b">Iodinated contrast media allergic-like reaction, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iodinated contrast media allergic-like reaction, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Generally reserved for patients with a prior allergic-like or unknown-type iodinated contrast reaction who will be receiving another iodinated contrast agent. Nonurgent premedication with an oral corticosteroid is generally preferred when contrast administration is scheduled to begin in ≥12 hours; however, consider an urgent (accelerated) regimen with an IV corticosteroid (eg, methylprednisolone) for those requiring contrast in &lt;12 hours. Efficacy of premedication regimens starting &lt;4 to 5 hours before the use of contrast has not been demonstrated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonurgent regimen:</i>
<b>Oral:</b> 50 mg administered 13 hours, 7 hours, and 1 hour before contrast medium administration in combination with diphenhydramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c47c9a24-145e-45a7-8ca2-e2a1b8ceb2ce">Minimal change disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minimal change disease, treatment (off-label use):</b> Initial therapy: <b>Oral:</b> 1 mg/kg/day (maximum: 80 mg/day) once daily <b>or</b> 2 mg/kg every other day (maximum: 120 mg every other day) for 4 to 16 weeks (if no response by 16 weeks, patient is most likely glucocorticoid resistant); ~2 weeks after achieving complete remission, gradually taper (eg, decrease by 5 to 10 mg/week for a total period of glucocorticoid exposure of up to 6 months); the duration of initial pulse therapy and tapering schedule can vary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23431071','lexi-content-ref-34556256','lexi-content-ref-27940460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23431071','lexi-content-ref-34556256','lexi-content-ref-27940460'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d5e175a-b72b-403f-a24e-a302277e849b">Multiple myeloma, previously untreated; transplant ineligible</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma, previously untreated; transplant ineligible</b>
<b>(off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">≥65 years of age or &lt;65 years of age and transplant ineligible: <b>Oral:</b> 60 mg/m<sup>2</sup>/day for 4 days (days 1 to 4) every 6 weeks for 9 cycles (dexamethasone at a dose of 20 mg was substituted for prednisone on day 1 of each cycle) in combination with daratumumab, bortezomib, and melphalan; after cycle 9, daratumumab is continued as a single agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29231133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29231133'])">Ref</a></span>) <b>or</b> 60 mg/m<sup>2</sup>/day for 4 days (days 1 to 4) every 6 weeks (in combination with bortezomib and melphalan) for 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18753647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18753647'])">Ref</a></span>) <b>or</b> 2 mg/kg/day for 4 days (days 1 to 4) every 6 weeks (in combination with melphalan and thalidomide) for 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17920916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17920916'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">≥65 years of age: <b>Oral:</b> 2 mg/kg/day for 4 days (days 1 to 4) every 6 weeks (in combination with melphalan) for 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16174762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16174762'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e6dff87-980d-4d42-adcd-93ba292bb21e">Multiple sclerosis, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple sclerosis, acute exacerbation: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients with an acute exacerbation resulting in neurologic symptoms and increased disability or impairments in vision, strength, or cerebellar function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olek.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olek.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial pulse therapy using an oral glucocorticoid (alternative agent to IV methylprednisolone pulse therapy):</i>
<b>Oral:</b> 625 mg to 1.25 g daily for 3 to 7 days (5 days typically), either alone or followed by a taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15452302','lexi-content-ref-Olek.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15452302','lexi-content-ref-Olek.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Taper following IV methylprednisolone or prednisone pulse therapy: </i>
<b>Oral:</b> 1 mg/kg/day (maximum: 80 mg/day), followed by a taper; total duration of oral therapy is usually 11 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507531','lexi-content-ref-16513709','lexi-content-ref-19566504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507531','lexi-content-ref-16513709','lexi-content-ref-19566504'])">Ref</a></span>). Tapering schedules vary and some experts prefer to omit taper following initial pulse glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Olek.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Olek.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c0a8a050-cc71-45aa-bc5d-3cac3c9c461a">Myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myasthenia gravis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute exacerbation (adjunctive therapy):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For severe exacerbations, use in conjunction with or several days following initiation of immune globulin IV or plasma exchange, as high-dose glucocorticoids may transiently worsen myasthenic weakness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-27358333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 mg/kg once daily (usual dose range: 60 to 80 mg daily), followed by an individualized taper as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-Bird.2','lexi-content-ref-16377829']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-Bird.2','lexi-content-ref-16377829'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic immunosuppression:</i> Oral:</b> 10 to 20 mg once daily; may increase in 5 mg/day increments every 3 to 7 days to a target dose of 60 to 80 mg daily, followed by an individualized gradual taper as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bird.1','lexi-content-ref-27358333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bird.1','lexi-content-ref-27358333'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c1492fd-1240-46a0-a8e1-affa8298a29c">Myopathies, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myopathies (dermatomyositis/polymyositis), treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial therapy (or following initial therapy with pulse IV methylprednisolone in select patients):</i>
<b> Oral:</b> 1 mg/kg/day (maximum: 80 mg/day) as a single daily dose until improvement (usually for 4 to 6 weeks); then gradually tapered (total duration usually 9 to 12 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365201','lexi-content-ref-25641317','lexi-content-ref-Targoff.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365201','lexi-content-ref-25641317','lexi-content-ref-Targoff.2022'])">Ref</a></span>). <b>Note:</b> Continuing high dose (1 mg/kg/day) for more than 6 weeks may increase risk of developing glucocorticoid-associated myopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Targoff.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Targoff.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="236d546c-b735-4016-861b-18e58e48239e">Pericarditis, acute or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pericarditis, acute or recurrent (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used for patients with contraindications or incomplete response to nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine. Glucocorticoid therapy early in the course of pericarditis is more likely to be associated with recurrent episodes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320112','lexi-content-ref-Imazio.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320112','lexi-content-ref-Imazio.2022'])">Ref</a></span>). Glucocorticoid therapy should be avoided in patients with pericarditis secondary to acute myocardial infarction given lack of benefit and potential harm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23256914','lexi-content-ref-LeWinter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23256914','lexi-content-ref-LeWinter.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.2 to 0.5 mg/kg/day until resolution of symptoms for at least 24 hours and normalization of inflammatory biomarkers (eg, C-reactive protein) if monitored; the initial dose is typically continued for 2 to 4 weeks then gradually tapered over 2 to 3 months if patient remains asymptomatic and inflammatory biomarkers remain normal (if monitored). Use in combination with colchicine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26320112','lexi-content-ref-Imazio.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26320112','lexi-content-ref-Imazio.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a91e469d-5047-4382-8fc7-9e8aba1103ca">
<i>Pneumocystis </i>pneumonia, adjunctive therapy for moderate to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Pneumocystis</i> pneumonia, adjunctive therapy for moderate to severe disease (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for patients with PaO<sub>2 </sub>&lt;70 mm Hg on room air or PAO<sub>2</sub>-PaO<sub>2</sub> ≥35 mm Hg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>); some experts additionally recommend for patients with oxygen saturation &lt;92% on room air (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sax.2020','lexi-content-ref-Thomas.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sax.2020','lexi-content-ref-Thomas.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg twice daily on days 1 to 5 beginning as early as possible, followed by 40 mg once daily on days 6 to 10, then 20 mg once daily on days 11 to 21 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-23465020','lexi-content-ref-Sax.2020','lexi-content-ref-Thomas.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-23465020','lexi-content-ref-Sax.2020','lexi-content-ref-Thomas.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee6b9e3e-5491-415a-b1e1-7b222fa74533">Poison ivy dermatitis, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Poison ivy dermatitis, severe (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an adjunct to topical therapies in patients with severe or extensive dermatitis (eg, covering &gt;50% of body surface, involvement of genitals and/or face) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11868634','lexi-content-ref-Prok.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11868634','lexi-content-ref-Prok.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> The optimal dosing strategy has not been defined; an example regimen is 1 mg/kg/day (maximum: 60 mg/day) as a single daily dose initially, followed by a taper over 2 to 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11376396','lexi-content-ref-Prok.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11376396','lexi-content-ref-Prok.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ffa0d2d-ce3f-4ab1-8db0-b09faaa087ad">Polymyalgia rheumatica</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polymyalgia rheumatica:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Goal of therapy is to alleviate symptoms; therapy has not been shown to improve prognosis or prevent progression to giant cell arteritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Salvarani.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Salvarani.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: Usual dose: 15 mg/day in a single daily dose or in divided doses; some experts consider lower initial doses of 7.5 to 10 mg/day for smaller patients with mild symptoms or at high risk for side effects (eg, labile diabetes) and higher initial doses of 20 mg/day (or 25 mg/daily [rarely]) for patients with more severe symptoms. Divided doses may help with pain and stiffness in evenings and following morning. Once symptoms are controlled, maintain dose for 2 to 4 weeks and gradually taper (generally over a 1- to 2-year period); some patients may require longer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30904473','lexi-content-ref-26359488','lexi-content-ref-Salvarani.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30904473','lexi-content-ref-26359488','lexi-content-ref-Salvarani.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant (off-label use</b>
<b>):</b>
<b>Oral:</b> 5 mg twice daily (in combination with abiraterone) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21612468','lexi-content-ref-25601341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21612468','lexi-content-ref-25601341'])">Ref</a></span>) <b>or</b> 10 mg once daily (in combination with cabazitaxel) for up to 10 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20888992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20888992'])">Ref</a></span>) <b>or</b> 5 mg twice daily (in combination with docetaxel) for up to 10 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182665','lexi-content-ref-15470213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182665','lexi-content-ref-15470213'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="32a9fd3d-616a-4974-a57c-1aaac2930727">Systemic rheumatic disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic rheumatic disorders (eg, antineutrophil cytoplasmic antibody-associated vasculitis, mixed cryoglobulinemia syndrome, polyarteritis nodosa, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The following dosage ranges are for guidance only; dosing should be highly individualized, taking into account disease severity, the specific disorder, and disease manifestations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Mild to moderate disease:</b></i>
<b>Oral:</b> Initial: 5 to 30 mg/day in a single daily dose or in divided doses, then taper to the minimum effective dose, depending on response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ACR.1','lexi-content-ref-Cohen.2','lexi-content-ref-34140301','lexi-content-ref-Fervenza.2020','lexi-content-ref-ODell.2020','lexi-content-ref-Wallace.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ACR.1','lexi-content-ref-Cohen.2','lexi-content-ref-34140301','lexi-content-ref-Fervenza.2020','lexi-content-ref-ODell.2020','lexi-content-ref-Wallace.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Severe disease:</i></b> Initial therapy (or following initial therapy with pulse IV methylprednisolone in select patients):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dose: Initial: 1 mg/kg/day (maximum: 60 to 80 mg/day) in a single daily dose or in divided doses; typically given for several weeks, then tapered gradually; may be given as part of an appropriate combination regimen; for severe systemic lupus erythematosus, up to 2 mg/kg/day may be given initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fervenza.2020','lexi-content-ref-27799164','lexi-content-ref-21303705','lexi-content-ref-Wallace.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fervenza.2020','lexi-content-ref-27799164','lexi-content-ref-21303705','lexi-content-ref-Wallace.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3366b908-8b85-4957-b3ac-11825415246c">Takayasu arteritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Takayasu arteritis (off-label use):</b>
<b>Oral:</b> Initial: 40 to 60 mg daily in combination with appropriate steroid-sparing agent; gradually taper to lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20359588','lexi-content-ref-31270110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20359588','lexi-content-ref-31270110'])">Ref</a></span>); some experts initiate treatment with 1 mg/kg/day (maximum: 60 to 80 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Merkel.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Merkel.2020'])">Ref</a></span>). <b>Note: </b>Long-term therapy may be required to prevent progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20359588','lexi-content-ref-Merkel.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20359588','lexi-content-ref-Merkel.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="492dec39-0471-4890-bbb6-9b1d2b2cd348">Thyroid eye disease, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid eye disease, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to IV glucocorticoids (eg, methylprednisolone); in patients with sight-threatening disease (eg, compressive optic neuropathy), urgent administration of IV glucocorticoids is required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36480280','lexi-content-ref-34297684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36480280','lexi-content-ref-34297684'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 60 to 100 mg once daily for 7 days, then gradually taper dose by 5 to 10 mg/week over 4 to 6 months based on clinical response and then discontinue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9532337','lexi-content-ref-34297684','lexi-content-ref-15998777','lexi-content-ref-11502779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9532337','lexi-content-ref-34297684','lexi-content-ref-15998777','lexi-content-ref-11502779'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="23cc21c5-d02f-41f5-8198-d657e8c9ae41">Thyroiditis, subacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroiditis, subacute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients whose pain does not respond to full dose of NSAIDs over several days <b>or </b>patients who present initially with moderate to severe pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 40 mg/day for 1 to 2 weeks; gradually taper (eg, by 5 to 10 mg/day every 5 to 7 days) based on clinical response. If pain recurs, increase to the lowest dose that controlled the pain; maintain that dose for ~2 weeks and attempt to taper again (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Burman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Burman.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ca4f8ab-6c12-48ba-81d2-a50f4fd15be0">Tuberculosis, pulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, pulmonary (prevention of immune reconstitution inflammatory syndrome in HIV-infected patients) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in antiretroviral-naive patients with CD4 count ≤100 cells/mm<sup>3</sup> who start antiretroviral therapy within 30 days of antituberculosis therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30428290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30428290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg once daily for 14 days, followed by 20 mg once daily for 14 days, during the first 4 weeks after initiation of antiretroviral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30428290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30428290'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9725631-1768-4934-bc00-6ca8a49c5f2e">Urticaria, chronic spontaneous, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, chronic spontaneous, acute exacerbation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For the temporary control of severe exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-34536239','lexi-content-ref-25711134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-34536239','lexi-content-ref-25711134'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 35 to 40 mg once daily until symptoms are controlled (usually occurs after 2 to 3 days of therapy), then taper by 5 to 10 mg/day over a period of 1 to 3 weeks followed by discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Khan.2020','lexi-content-ref-25711134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Khan.2020','lexi-content-ref-25711134'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="992a0682-8a0f-4293-8ad0-146fa7ebf6a0">Warm autoimmune hemolytic anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warm autoimmune hemolytic anemia: Oral:</b> 1 to 2 mg/kg/day until a hemoglobin response has occurred (typically within 1 to 3 weeks). After hemoglobin stabilization, begin tapering to the lowest dose to maintain remission followed by gradual tapering with an eventual goal of discontinuation (total duration of therapy: 3 to 12 months); a clinician experienced with the treatment of hemolytic anemia should be involved with therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20656187','lexi-content-ref-31412178','lexi-content-ref-24847759','lexi-content-ref-25271314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20656187','lexi-content-ref-31412178','lexi-content-ref-24847759','lexi-content-ref-25271314'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990439"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The pharmacokinetics and pharmacodynamics of prednisone in kidney impairment are not well understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23018468','lexi-content-ref-15634032','lexi-content-ref-25471548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23018468','lexi-content-ref-15634032','lexi-content-ref-25471548'])">Ref</a></span>). Prednisolone (active metabolite) clearance is reduced ~40% in patients with uremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6880855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6880855'])">Ref</a></span>) and is minimally dialyzable (≤17.5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6751835']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6751835'])">Ref</a></span>); however, the clinical implications of these findings are unclear.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987629"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F57253281"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥</b>
<b>30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Non–weight-based dosing: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-based dosing: Use <b>ideal body weight</b> to avoid overdosing and subsequent toxicity, especially with longer durations of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b> Corticosteroids are lipophilic compounds; however, the reported pharmacokinetic variability due to obesity is limited and inconsistent. One small study in patients with asthma reported higher prevalence of abnormal prednisone absorption and fast prednisolone clearance when BMI exceeded 25 kg/m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26795244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26795244'])">Ref</a></span>). A second small study in males with obesity described increases in both volume of distribution and clearance following IV prednisolone administration compared to males without obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6499362']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6499362'])">Ref</a></span>). The clinical significance of these pharmacokinetic changes requires further study, especially in patients with BMI ≥40 kg/m<sup>2</sup>, where there are minimal data. Glucocorticoid pharmacodynamics may be enhanced in obesity; weight-based dosing using actual body weight could lead to supratherapeutic levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30928086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30928086'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F213104"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use the lowest effective dose.</p></div>
<div class="block dop drugH1Div" id="F213125"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12725" href="/d/html/12725.html" rel="external">see "Prednisone: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Individualize dosing and use the lowest possible dose to control the condition; when dose reduction is possible, reduce dose gradually. Consider alternate day therapy for long-term therapy. All pediatric dosing is based on IR products; patients switching from IR product to delayed-release product (eg, Rayos) should be dosed based on relative potency.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>National Asthma Education and Prevention Program guidelines</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Acute exacerbation (emergency care or hospital doses):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;12 years: Oral: 1 to 2 mg/kg/day in 2 divided doses, continue until peak expiratory flow is 70% of predicted or personal best; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 40 to 80 mg in divided doses 1 to 2 times daily until peak expiratory flow is 70% of predicted or personal best.</p>
<p style="text-indent:-2em;margin-left:6em;">Short-course "burst" (outpatient acute asthma):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;12 years: Oral: 1 to 2 mg/kg/day in divided doses 1 to 2 times daily for 3 to 10 days; maximum daily dose: 60 mg/<b>day</b>; <b>Note:</b> Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 40 to 60 mg in divided doses 1 to 2 times daily for 3 to 10 days; <b>Note:</b> Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3 to 10 days of treatment (~5 days on average); longer treatment may be required.</p>
<p style="text-indent:-2em;margin-left:6em;">Long-term treatment for severe, persistent asthma (nonacute):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;12 years: Oral: 0.25 to 2 mg/kg/day given as a single dose in the morning or every other day as needed for asthma control; maximum daily dose: 60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: Oral: 7.5 to 60 mg daily given as a single dose in the morning or every other day as needed for asthma control.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Global Initiative for Asthma guidelines</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1'])">Ref</a></span>): Management in primary care or acute care facility:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;12 years: Oral: 1 to 2 mg/kg/day for 3 to 5 days.</p>
<p style="text-indent:-2em;margin-left:8em;">Maximum daily dose age-dependent:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children ≤2 years: 20 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 3 to 5 years: 30 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Children 6 to 11 years: 40 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 1 mg/kg/day for 5 to 7 days; maximum daily dose: 50 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35fc3185-d805-4f94-b5b3-969b89fe8248">Bell palsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bell palsy:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents &lt;16 years: Optimal regimen not defined: Oral: 1 to 2 mg/kg/day for 5 to 7 days, followed by a 7-day taper. Begin treatment within 72 hours of onset of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16198208','lexi-content-ref-24141272','lexi-content-ref-Kliegman.2020','lexi-content-ref-22503409']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16198208','lexi-content-ref-24141272','lexi-content-ref-Kliegman.2020','lexi-content-ref-22503409'])">Ref</a></span>). Adult maximum daily dose: 60 mg/<b>day</b>. Pediatric patients with Bell palsy may experience spontaneous recovery, even without treatment; potential benefit of treatment is unclear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24189771','lexi-content-ref-16198208','lexi-content-ref-24141272']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24189771','lexi-content-ref-16198208','lexi-content-ref-24141272'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: Oral: 60 mg daily for 5 days, followed by a 5-day taper. Treatment should begin within 72 hours of onset of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24189771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24189771'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afa687ed-131c-4dd7-b289-81195205fdfc">Congenital adrenal hyperplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia: Note:</b> Individualize dose by monitoring growth, hormone levels, and bone age; mineralocorticoid (eg, fludrocortisone) and sodium supplement may be required in salt losers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents (fully grown): Oral: 5 to 7.5 mg daily in divided doses 2 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>). <b>Note:</b> For younger patients who are still growing, hydrocortisone or fludrocortisone are preferred.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease:</b>
<b>Note: </b>Use for induction in patients with active luminal disease if exclusive enteral nutrition is poorly tolerated or ineffective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33026087']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33026087'])">Ref</a></span>). Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Children and Adolescents: Oral: 1 to 2 mg/kg/day; maximum daily dose: 60 mg/<b>day</b>; continue for 2 to 4 weeks until remission, then gradually taper over 4 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2020','lexi-content-ref-22516861','lexi-content-ref-20081543']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2020','lexi-content-ref-22516861','lexi-content-ref-20081543'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dose</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33026087']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33026087'])">Ref</a></span>): Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">10 to 20 kg: Oral: 20 mg once daily until clinical remission or a maximum of 4 weeks (whichever occurs first) followed by tapering in 2.5 to 5 mg increments every 5 to 7 days. Goal to discontinue by ≤10 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to 30 kg: Oral: 30 mg once daily until clinical remission or a maximum of 4 weeks (whichever occurs first) followed by tapering in 5 mg increments every 5 to 7 days. Goal is to discontinue by ≤10 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 kg: Oral: 40 mg once daily until clinical remission or a maximum of 4 weeks (whichever occurs first) followed by tapering in 5 mg increments every 5 to 7 days. Goal is to discontinue by ≤10 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41052d41-e168-4342-98e3-cba3205ee0c3">Dermatomyositis, juvenile</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis, juvenile:</b> Limited data available: Children and Adolescents: Oral: 1 to 2 mg/kg/day; usual recommended maximum daily dose: 60 mg/<b>day</b>; higher doses of 80 mg/day have also been reported; continue for 4 weeks then if adequate patient response, begin taper; taper dose by 0.5 mg/kg increments every 2 weeks based on response until dose is 0.5 mg/kg/day, then taper every 4 weeks as tolerated; optimal duration is unknown; use in combination with other immunosuppressants (eg, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20191521','lexi-content-ref-27803135','lexi-content-ref-22076847','lexi-content-ref-28077146','lexi-content-ref-27515057','lexi-content-ref-29940960']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20191521','lexi-content-ref-27803135','lexi-content-ref-22076847','lexi-content-ref-28077146','lexi-content-ref-27515057','lexi-content-ref-29940960'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cc06b31-bbc9-4530-9118-12d395c83705">Duchenne muscular dystrophy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Duchenne muscular dystrophy (DMD):</b> Children ≥4 years and Adolescents: Oral: Usual recommended dose: 0.75 mg/kg/day; maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937','lexi-content-ref-21753160','lexi-content-ref-2039377','lexi-content-ref-27149418','lexi-content-ref-2657428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937','lexi-content-ref-21753160','lexi-content-ref-2039377','lexi-content-ref-27149418','lexi-content-ref-2657428'])">Ref</a></span>). If adverse effects persist, continue to gradually taper to as low as 0.3 mg/kg/day, which may provide benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937'])">Ref</a></span>). Doses as high as 1.5 mg/kg/day have been studied, but there is no evidence that doses &gt;0.75 mg/kg/day provide greater efficacy and they are associated with more adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26833937','lexi-content-ref-2039377','lexi-content-ref-27149418','lexi-content-ref-2657428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26833937','lexi-content-ref-2039377','lexi-content-ref-27149418','lexi-content-ref-2657428'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="72c5a8aa-8a91-445e-bf5b-2a2891c880bd">Hepatitis, autoimmune</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis, autoimmune (monotherapy or in combination with azathioprine):</b> Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mg/kg/day until biochemical remission is achieved; maximum daily dose: 60 mg/<b>day</b>; lower maximum daily dose (eg, 40 mg/<b>day) </b>recommended when administering in combination with azathioprine; taper upon response over ~4 to 8 weeks to a dose of 0.1 to 0.3 mg/kg/day or 2.5 to 5 mg daily; an alternate day schedule to decrease risk of adverse effect has been used; however, a higher incidence of relapse has been observed in some cases and use is not suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31863477','lexi-content-ref-22495399','lexi-content-ref-26341719','lexi-content-ref-29356770','lexi-content-ref-Kliegman.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31863477','lexi-content-ref-22495399','lexi-content-ref-26341719','lexi-content-ref-29356770','lexi-content-ref-Kliegman.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6bd6a70-bdd8-4d1d-ac83-e21924f67c5f">Immune thrombocytopenia, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune thrombocytopenia (ITP), newly diagnosed (non-life threatening bleeding):</b> Variable regimens reported: Infants, Children, and Adolescents: Oral: Initial: 2 to 4 mg/kg/day in 3 to 4 divided doses for 5 to 7 days; maximum daily dose: 120 mg/<b>day</b>; higher maximum doses of 200 mg/<b>day</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31794604','lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31794604','lexi-content-ref-31770441'])">Ref</a></span>); alternatively, 1 to 2 mg/kg/<b>day</b> up to 80 mg/<b>day</b> for 1 to 2 weeks followed by a taper with goal of discontinuing therapy by 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31770441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31770441'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5448515f-97ae-43ca-9219-ac99b16a79f6">Infantile hemangioma, second-line treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infantile hemangioma, second-line treatment: Note: </b>Use if oral propranolol is contraindicated, poorly tolerated, or produces inadequate response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30584062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30584062'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: Oral: 2 to 3 mg/kg/day up to 5 mg/kg/day; may be administered once daily or in divided doses up to 4 times daily; duration depends on response rate, patient age, and phase of hemangioma growth, but usually ranges from 4 to 12 weeks followed by a gradual taper and completion of therapy by 9 to 12 months of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-11205840','lexi-content-ref-11559219','lexi-content-ref-11359498','lexi-content-ref-21572374','lexi-content-ref-10890993','lexi-content-ref-8551406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26416931','lexi-content-ref-30584062','lexi-content-ref-11205840','lexi-content-ref-11559219','lexi-content-ref-11359498','lexi-content-ref-21572374','lexi-content-ref-10890993','lexi-content-ref-8551406'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7bfa6a19-11be-4097-9456-7c7ce2ad756d">Juvenile idiopathic arthritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Juvenile idiopathic arthritis (JIA): Note:</b> Therapy should be individualized based on type of JIA as well as disease severity and activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31021516','lexi-content-ref-22290637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31021516','lexi-content-ref-22290637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Polyarticular JIA: </i>
<b>Note:</b> In patients with polyarticular JIA with high or moderate disease activity, bridging therapy with a limited course (&lt;3 months) of oral glucocorticoids during initiation or escalation of therapy is recommended; chronic low dose glucocorticoids is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31021516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31021516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24339215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24339215'])">Ref</a></span>): Variable regimens reported:</p>
<p style="text-indent:-2em;margin-left:8em;">Low dose: Oral: 0.25 mg/kg/day; maximum daily dose: 20 mg/<b>day</b>; after 1 week begin tapering dose by decreasing dose to 0.125 mg/kg/day, then in 3 to 4 days, decrease to 0.05 mg/kg/day and discontinue after a total of 2 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Medium dose: Oral: 0.5 mg/kg/day; maximum daily dose: 30 mg/<b>day</b>; after 1 week begin taper by decreasing dose to 0.4 mg/kg/day for 7 days, then decrease to 0.25 mg/kg/day for 7 days and then 0.1 mg/kg/day for 7 days; discontinue after a total of 4 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">High dose: Oral: 1 mg/kg/day; maximum daily dose: 60 mg/<b>day</b>; begin tapering dose after 1 to 2 weeks; decrease dose in 0.25 mg/kg/day increments every 1 to 4 weeks; tapering duration varies with some tapering doses over 4 weeks and others use a slower taper and taper off over 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic JIA: </i>Infants ≥6 months, Children, and Adolescents: Oral: Initial: 1 mg/kg/day administered once daily (initial maximum daily dose: 60 mg/<b>day</b>); may be used in combination with methylprednisolone pulse therapy; evaluate initial response at 1 to 2 weeks and then at 1 month of therapy; if patient improves then taper prednisone, if unchanged then continue current prednisone therapy and if worsened then increase dose to 2 mg/kg/day (maximum daily dose: 100 mg/<b>day</b>). After 1 month, if improvement, begin taper; if condition worsens or unchanged then increase or continue prednisone dose at 2 mg/kg/day (maximum daily dose: 100 mg/<b>day</b>) and/or may add or repeat methylprednisolone pulse therapy. After 3 months of glucocorticoid therapy, if improvement (prednisone dose &lt;50% starting dose), continue taper and reassess monthly; if patient remains unchanged (prednisone dose &gt;50% of starting dose) or worsened, additional therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22290637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22290637'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19c008f2-35a9-48bb-a78b-3b016b27a96a">Kawasaki disease, primary adjunctive treatment for patients at high risk for intravenous immune globulin resistance or coronary artery aneurysms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki disease (KD), primary adjunctive treatment for patients at high risk for intravenous immune globulin (IVIG) resistance or coronary artery aneurysms:</b> Limited data available: <b>Note:</b> Use to transition patients receiving IV corticosteroids for treatment of KD (in combination with IVIG and aspirin):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 2 mg/kg/day in divided doses every 8 hours until C-reactive protein (CRP) normalizes; maximum daily dose: 60 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-22405251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-22405251'])">Ref</a></span>). Some centers use less frequent dosing (eg, every 12 hours) to minimize adverse reactions (eg, effect on sleep) and for convenience (eg, ease of dosing at home). Once CRP normalized, taper over 15 days according to institutional practice (tapers may vary); a longer course, tapering over 2 to 3 weeks, may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-22405251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35257507','lexi-content-ref-28356445','lexi-content-ref-22405251'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eab8f0bd-af63-4233-929f-24083e3b8bec">Lupus nephritis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis:</b> Children and Adolescents: Oral: Initial therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>With concurrent methylprednisolone pulse therapy:</i> Prednisone: 0.5 to 1.5 mg/kg/day; maximum daily dose: 60 mg/<b>day</b>, taper usually over 6 months to a dose ≤10 mg/day according to clinical response; use in combination with cyclophosphamide or mycophenolate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851469','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408','lexi-content-ref-22162255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851469','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408','lexi-content-ref-22162255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Without concurrent methylprednisolone pulse therapy:</i> Prednisone: 2 mg/kg/day for 6 weeks, maximum daily dose variable: For weeks 1 to 4: Maximum daily dose: 80 mg/<b>day</b>; for weeks 5 and 6: Maximum daily dose: 60 mg/<b>day</b>; taper over 6 months; use in combination with cyclophosphamide or mycophenolate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22162255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22162255'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78c5f82f-cbc3-486c-93dc-297e6d7480ac">Nephrotic syndrome; steroid-sensitive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome; steroid-sensitive (SSNS):</b> Children and Adolescents: <b>Note:</b> Obese patients should be dosed based on ideal body weight: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial episode:</i> 2 mg/kg/day or 60 mg/<b>m<sup>2</sup></b>/day once daily, maximum daily dose: 60 mg/<b>day</b> for 4 to 6 weeks; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/<b>m<sup>2</sup></b>/dose on alternate days as a single dose, maximum dose: 40 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408'])">Ref</a></span>); prolonged durations have not been shown to reduce risk of relapse; treatment duration should be limited to 2 to 3 months for the first episode of SSNS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25785660','lexi-content-ref-25912994','lexi-content-ref-26289063']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25785660','lexi-content-ref-25912994','lexi-content-ref-26289063'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapse:</i> 2 mg/kg/day or 60 mg/<b>m<sup>2</sup></b>/day once daily, maximum daily dose: 60 mg/<b>day</b> continue until complete remission for at least 3 days; then adjust to an alternate-day schedule of 1.5 mg/kg/dose or 40 mg/<b>m<sup>2</sup></b>/dose on alternate days as a single dose, maximum dose: 40 mg/dose, recommended duration of alternate day dosing is variable: may continue for at least 4 weeks then taper. Longer duration of treatment may be necessary in patients who relapse frequently, some patients may require up to 3 months of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590','lexi-content-ref-KDIGO.1','lexi-content-ref-23871408'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance therapy for frequently relapsing SSNS:</i> Taper previous dose down to lowest effective dose which maintains remission using an alternate day schedule; usual effective range: 0.1 to 0.5 mg/kg/dose on alternating days; other patients may require doses up to 0.7 mg/kg/dose every other day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.1','lexi-content-ref-23871408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.1','lexi-content-ref-23871408'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3570d6ef-f7f5-425c-9464-7d0146fea1c1">Physiologic replacement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b> Physiologic replacement:</b> Children and Adolescents: Oral: 2 to 2.5 mg/<b>m<sup>2</sup></b>/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21867553','lexi-content-ref-19023528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21867553','lexi-content-ref-19023528'])">Ref</a></span>). <b>Note:</b> Hydrocortisone is generally preferred in growing children and adolescents due to its lower growth suppressant effects compared to prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19023528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19023528'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f2399b0-2c49-4531-9fe5-051c2ca51d64">
<i>Pneumocystis jirovecii</i> pneumonia, adjunctive treatment; HIV-exposed/-infected</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Pneumocystis jirovecii </b></i>
<b>pneumonia (PCP), adjunctive treatment; HIV-exposed/-infected: Note:</b> Begin as soon as possible after diagnosis and within 72 hours of PCP therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 1 mg/kg/dose twice daily on days 1 to 5, then 0.5 to 1 mg/kg/dose twice daily on days 6 to 10, then 0.5 mg/kg/dose once daily for days 11 to 21 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 40 mg twice daily on days 1 to 5, followed by 40 mg once daily on days 6 to 10, and then 20 mg once daily on days 11 to 21 or until antimicrobial regimen is completed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="28590e42-e7f9-435a-976a-9ca55340b4d3">Ulcerative colitis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, moderate to severe:</b>
<b>Note: </b>Not for long-term maintenance; use for induction only.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 1 to 2 mg/kg/day administered in the morning for 2 to 3 weeks; maximum daily dose: 60 mg/<b>day</b>; if no response after 7 to 14 days optimal dosing and compliance should be assessed; after the initial 2 to 3 weeks, the dose is gradually decreased over 8 to 10 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357','lexi-content-ref-Kliegman.2020','lexi-content-ref-22516861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357','lexi-content-ref-Kliegman.2020','lexi-content-ref-22516861'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154935"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51154936"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Prednisone is inactive and must be metabolized by the liver to prednisolone. This conversion may be impaired in patients with liver disease; however, prednisolone levels are observed to be higher in patients with severe liver failure than in normal patients. Therefore, compensation for the inadequate conversion of prednisone to prednisolone occurs.</p></div>
<div class="block arsc drugH1Div" id="F55158127"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Adrenal suppression (tertiary adrenal insufficiency)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenal suppression</b> (tertiary adrenal insufficiency) may occur with glucocorticoids, including prednisone, and results from inadequate stimulation of the adrenal glands (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahosi.1','lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahosi.1','lexi-content-ref-31223468'])">Ref</a></span>). Glucocorticoid-induced adrenal insufficiency usually resolves with discontinuation of prednisone, but symptoms may persist for 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34253540','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34253540','lexi-content-ref-29184808'])">Ref</a></span>). Adrenal insufficiency may lead to adrenal crisis, a life-threatening emergency that may present like a hypotensive shock state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; occurs due to lack of or diminished cortisol production which is decreased by the adrenal gland (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). Exogenous glucocorticoids produce a similar negative feedback mechanism as endogenous cortisol, causing a subsequent decrease in adrenocorticotrophic hormone (ACTH) secretion; thus, cortisol production is suppressed, resulting in adrenal atrophy and subsequent insufficiency (ie, hypothalamic-pituitary-adrenal-axis [HPA-axis] suppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468','lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468','lexi-content-ref-29184808'])">Ref</a></span>). In times of stress (eg, critical illness, trauma, surgery), the body requires stress doses in patients taking prednisone chronically (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; acute (minutes after administration) and/or chronic (2 to 20 hours to days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>). Chronic prednisone use does not allow for the HPA axis to recover quickly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29184808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29184808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses for prolonged periods: Although some patients may become HPA suppressed with lower doses or briefer exposure, some experts consider HPA-axis suppression likely in any adult receiving &gt;20 mg/day (daytime dosing) or ≥5 mg per 24 hours (evening or night dosing) for &gt;3 weeks or with cushingoid appearance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27105755','lexi-content-ref-33923971']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27105755','lexi-content-ref-33923971'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Potency of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent interacting medications (eg, carbamazepine, St John's wort, mitotane, rifampicin, itraconazole, diltiazem, thyroid replacement therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of previous adrenal crisis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31223468']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31223468'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of glucocorticoid therapy delivered by various routes of administration (oral and inhaled greater risk than topical or intra-articular) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Akahosi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Akahosi.1'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prednisone has potent cardiovascular effects which include <b>hypertension</b>, <b>dyslipidemia</b>, <b>fluid retention</b>, electrolyte disturbances (<b>decreased serum potassium</b>, <b>sodium retention</b>), and arrhythmias (from rare cases of <b>bradycardia</b> to more common reports of <b>atrial fibrillation</b>). Fluid retention can worsen <b>cardiac failure</b> in some patients because of its mineralocorticoid properties (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15545676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15545676'])">Ref</a></span>). Prednisone can increase blood pressure in a dose-dependent manner. Dyslipidemia occurring with long-term prednisone use manifests as increased total cholesterol, low density lipoprotein, and triglycerides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15253942','lexi-content-ref-10787466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15253942','lexi-content-ref-10787466'])">Ref</a></span>). Chronic glucocorticoid use has been associated with an increased risk of developing cardiovascular disease/events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15253953','lexi-content-ref-15545676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15253953','lexi-content-ref-15545676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; prednisone increases systemic vascular resistance (hypertension), increases extracellular volume (fluid retention), and increases cardiac contractility (potentiating atrial fibrillation/flutter). It is the combination of these cardiac effects (hypertension and edema) in patients with hyperglycemia and obesity that can lead to metabolic syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10787466']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10787466'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. Prednisone-induced hypertension: One type occurs in patients without risk factors early in therapy and a second (more classic) type occurs with weight gain and adipose tissue redistribution later in therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25204470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25204470'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-23947590','lexi-content-ref-29741130','lexi-content-ref-7576399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-23947590','lexi-content-ref-29741130','lexi-content-ref-7576399'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of essential hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-7576399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-7576399'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29752705','lexi-content-ref-23947590','lexi-content-ref-29741130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29752705','lexi-content-ref-23947590','lexi-content-ref-29741130'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pulse therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-7576399']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25978108','lexi-content-ref-26096556','lexi-content-ref-7576399'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS and psychiatric/behavioral effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including prednisone, may cause a myriad of CNS and psychiatric/behavioral adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>). Patients may develop <b>apathy</b> or <b>depression</b>. More commonly, patients develop excitatory <b>psychiatric disturbances</b> (including agitation, anxiety, distractibility, fear, hypomania, insomnia, irritability, lethargy, labile mood, mania, pressured speech, restlessness, and tearfulness) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696'])">Ref</a></span>). Exact incidences are unclear but range from 1.8% to 57% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17036562'])">Ref</a></span>). Severe psychiatric effects have been reported in 6% of adults receiving high-dose regimens, while depression or mania have been reported in 36% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696'])">Ref</a></span>). Discontinuation or dose reductions generally resolve symptoms over days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24943696','lexi-content-ref-26034636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24943696','lexi-content-ref-26034636'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; not clearly established. Prednisone and other corticosteroids may alter feedback on the hypothalamic-pituitary-adrenal axis, which may lead to mood changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31656440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31656440'])">Ref</a></span>). Glucocorticoids may induce glutamate release, which may be responsible for neuronal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992'])">Ref</a></span>). Exogenous glucocorticoids may also inhibit synthesis of cortical GABAergic steroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23157995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23157995'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; most cases occur early in treatment (within the first 5 days), average of 11.5 days. The majority develop within 6 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-26034636','lexi-content-ref-17036562'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (≥80 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24347992','lexi-content-ref-24943696','lexi-content-ref-17036562'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Possible additional risk factors:</i></p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;30 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17036562']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17036562'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of neuropsychiatric disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22764363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22764363'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cushingoid features/Cushing syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids may cause a<b> cushingoid appearance</b> (truncal obesity, facial adipose tissue, dorsocervical adipose tissue) which are adverse reactions related to patient's physical features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-23947590'])">Ref</a></span>). Reactions are more metabolic than <b>weight gain</b>, which is related to fluid retention (edema) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-23947590'])">Ref</a></span>). Iatrogenic <b>Cushing syndrome </b>resulting from glucocorticoid therapy increases morbidity and mortality and decreases quality of life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27177728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27177728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; excess cortisol from exogenous source (prednisone) results in suppression of adrenocorticotrophic hormone (ACTH), commonly called iatrogenic <b>Cushing syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15850848','lexi-content-ref-24910822']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15850848','lexi-content-ref-24910822'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; may develop within the first 2 months of prednisone therapy, with the risk dependent on the dose and duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-15850848','lexi-content-ref-18684744'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Drug interactions prolonging the half-life of glucocorticoids via cytochrome P450 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI (high) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Daily caloric intake (&gt;30 kcal/kg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including prednisone, may cause GI effects, including <b>peptic ulcer</b> (with possible perforation and hemorrhage), dyspepsia, gastritis, <b>abdominal distention</b>, and <b>ulcerative esophagitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>). Meta-analyses suggest that glucocorticoid monotherapy carries little to no risk of peptic ulcer disease in the general population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27986133','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27986133','lexi-content-ref-23947590'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; glucocorticoids inhibit gastroprotective prostaglandin synthesis and reduce gastric mucus and bicarbonate secretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23919213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23919213'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (equivalent to methylprednisolone ≥4 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-11390328','lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21357821','lexi-content-ref-23919213','lexi-content-ref-11390328','lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized (but not ambulatory) patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24833682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24833682'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Recent glucocorticoid users (7 to 28 days) versus remote or nonusers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26096497']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26096497'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including prednisone, may provoke new-onset <b>hyperglycemia </b>in patients without a history of diabetes and may cause an <b>exacerbation of diabetes mellitus</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-26240704'])">Ref</a></span>). Glucose levels have been noted to increase 68% above baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704'])">Ref</a></span>). Certain patient populations (eg, transplant, cancer, chronic rheumatologic conditions) are at particular risk due to medication combinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580'])">Ref</a></span>). Resolution may occur within 12 to 16 hours after prednisone discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; increased insulin resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23090580','lexi-content-ref-22187441','lexi-content-ref-26240704'])">Ref</a></span>). May also interfere with insulin signaling by direct effects on the insulin receptor and the glucose transporter and may promote gluconeogenesis via liver stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; 4 hours, with a peak of 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26240704','lexi-content-ref-28836444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26240704','lexi-content-ref-28836444'])">Ref</a></span>). Rapid onset of steroid-induced hyperglycemia occurred within 2 days after initiation of glucocorticoids with a peak in the late afternoon following daily dosing in the morning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23298665','lexi-content-ref-26240704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23298665','lexi-content-ref-26240704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose and type of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Divided versus once-daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV and oral routes of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• BMI &gt;25 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• African American or Hispanic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• eGFR &lt;40 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HbA<sub>1c</sub> ≥6% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of gestational diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of mycophenolate mofetil and calcineurin inhibitors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous history of impaired fasting glucose or impaired glucose tolerance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29530386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29530386'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoids, including prednisone, have immunosuppressive and anti-inflammatory effects that are reversible with discontinuation. <b>Infection</b> may occur after prolonged use, including <i>Pneumocystis jirovecii pneumonia</i> (PJP), herpes zoster, tuberculosis, and other more common bacterial infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; related to pharmacologic action (ie, multiple activities on cell macrophage production and differentiation, inhibition of T-cell activation, and effects on dendritic cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8239251','lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8239251','lexi-content-ref-26611557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; in one study, the median duration of glucocorticoid use prior to PJP diagnosis was 12 weeks but also occurred earlier or later in some cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8538233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8538233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher dose and longer duration of glucocorticoid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055','lexi-content-ref-23137579'])">Ref</a></span>); however, may also increase risk at lower doses (eg, prednisone ≤5 mg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32956604']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32956604'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunocompromised state (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26611557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26611557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications (immunosuppressive) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rheumatoid arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23137579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23137579'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Interstitial lung disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22241902','lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22241902','lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Male (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low performance status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23982055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23982055'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neuromuscular and skeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoid (including prednisone)-induced neuromuscular and skeletal effects can take the form of various pathologies in patients ranging from <b>osteoporosis</b> and <b>vertebral compression fracture</b> to <b>myopathy</b> to <b>osteonecrosis</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Glucocorticoid use is the most common cause of secondary osteoporosis; may be underrecognized and undertreated due to underestimation of risk in this patient population (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17982350','lexi-content-ref-26509049','lexi-content-ref-25905379'])">Ref</a></span>). Vertebral fractures are the most common glucocorticoid-related fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>). Myopathies can also occur secondary to direct skeletal muscle catabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>). Acute <b>steroid myopathy</b> is rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462474'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; glucocorticoids have direct/indirect effects on bone remodeling with osteoblast recruitment decreasing and apoptosis increasing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>). Myopathies or <b>myasthenia</b> result from reductions in protein synthesis and protein catabolism, which can manifest as proximal muscle weakness and atrophy in the upper and lower extremities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; vertebral fracture risk is increased within 3 months of initiation and peaks at 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590','lexi-content-ref-19011472'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-related risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Cumulative dose of glucocorticoids prednisone &gt;5 g or equivalent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507','lexi-content-ref-23947590'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Children receiving ≥4 courses of glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17332238','lexi-content-ref-12733732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17332238','lexi-content-ref-12733732'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Prednisone ≥2.5 to 7.5 mg daily or equivalent for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Myopathy may occur at prednisone doses ≥10 mg daily, with higher doses potentiating more of a rapid onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Fluorinated glucocorticoid preparations (eg, dexamethasone, betamethasone, triamcinolone) have a higher risk of myopathies than prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">General fracture risks:</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;55 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• BMI &lt;18.5 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bone mineral T score below -1.5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Endocrine disorders (eg, hypogonadism, hyper- or hypoparathyroidism) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Excess alcohol use (&gt;2 units/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of falls (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Malabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Menopause and duration of menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26509049','lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26509049','lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• White race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Patients with cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20471889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20471889'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Previous fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Underlying inflammatory condition in all ages (eg, inflammatory bowel disease, rheumatoid arthritis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30586507','lexi-content-ref-17332238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30586507','lexi-content-ref-17332238'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Glucocorticoid (including prednisone)-induced ocular effects may include <b>increased intraocular pressure</b> (IOP), <b>glaucoma </b>(open-angle), and <b>subcapsular posterior</b>
<b>cataract</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15932528','lexi-content-ref-28924342','lexi-content-ref-21757964'])">Ref</a></span>). Cataracts may persist after discontinuation of glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21666852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21666852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; glucocorticoids can induce cataracts by covalently bonding to lens proteins, causing destabilization of the protein structure, and oxidative changes leading to cataracts formation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9464184','lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9464184','lexi-content-ref-28924342'])">Ref</a></span>). There are various proposed mechanisms of IOP contributing to glaucoma, including accumulation of polymerized glycosaminoglycans in the trabecular meshwork, producing edema and increasing outflow resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Another mechanism may include inhibition of phagocytic endothelial cells, leading to accumulation of aqueous debris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28924342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28924342'])">Ref</a></span>). Glucocorticoids can also alter the trabecular meshwork causing an increase in nuclear size and DNA content (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>). In addition, they can decrease the synthesis of prostaglandins which regulate the aqueous outflow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; cataracts may occur at least 1 year after initiation of chronic glucocorticoid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-3541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-3541262'])">Ref</a></span>). IOP may occur at 4 years or more after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Topical &gt; Systemic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of open-angle glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type I diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17900234','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17900234','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High myopia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23947590','lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23947590','lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pseudophakia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior vitrectomies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Connective tissue disease and sex (eg, rheumatoid arthritis in males) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients or age &lt;6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Angle recessive glaucoma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21757964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21757964'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F213067"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiomegaly, circulatory shock, edema, heart failure (in susceptible patients), hypertrophic cardiomyopathy (premature infants), myocardial rupture (after recent myocardial infarction), syncope, tachycardia, thrombophlebitis, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, diaphoresis, facial erythema, hyperpigmentation, hypopigmentation, skin atrophy, skin rash, thinning hair (scalp), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium, fluid retention, growth retardation (children), hirsutism, hypokalemic alkalosis, menstrual disease, negative nitrogen balance (due to protein catabolism), sodium retention, weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hiccups, increased appetite, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Asthenospermia, oligospermia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatomegaly, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sterile abscess</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal sensory symptoms, arachnoiditis, headache, increased intracranial pressure (with papilledema), malaise, meningitis, myasthenia, neuritis, neuropathy, paraplegia, paresthesia, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Charcot arthropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Wound healing impairment</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (van der Hooft 2006), hypertension (Mebrahtu 2020), venous thrombosis (Johannesdottir 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenal suppression (tertiary) (Broersen 2015), Cushing syndrome (iatrogenic) (Hopkins 2005), cushingoid appearance (Hopkins 2005), dyslipidemia (Vodnala 2012), exacerbation of diabetes mellitus (Tamez-Pérez 2015), hyperglycemia (Tamez-Pérez 2015), impaired glucose tolerance (Tamez-Pérez 2015), moon face (Hopkins 2005), redistribution of body fat (Hopkins 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (Liu 2013), peptic ulcer (with possible perforation and hemorrhage) (Liu 2013), ulcerative esophagitis (Liu 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Kaposi sarcoma (Trattner 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Polosa 1998)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (Youssef 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apathy (Ciriaco 2013; Warrington 2006), depression (Ciriaco 2013; Warrington 2006), psychiatric disturbance (dose-dependent; including agitation, anxiety, distractibility, euphoria, fear, hypomania, insomnia, irritability, labile mood, lethargy, pressured speech, restlessness, tearfulness) (Ciriaco 2013; Warrington 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Buckley 2018), myopathy (Liu 2013), osteonecrosis (femoral and humeral heads) (Liu 2013), osteoporosis (Buckley 2018), steroid myopathy (Haran 2018), vertebral compression fracture (Buckley 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma (Razeghinejed 2012), increased intraocular pressure (Phulke 2017), retinopathy (Tarabishy 2011) subcapsular posterior cataract (Urban 1986)</p></div>
<div class="block coi drugH1Div" id="F213082"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to prednisone or any component of the formulation; administration of live or live attenuated vaccines with immunosuppressive doses of prednisone; systemic fungal infections.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Herpes simplex of the eye, measles, or chickenpox (except when being used for short-term or emergency therapy); peptic ulcer; nonspecific ulcerative colitis; diverticulitis; viral or bacterial infection not controlled by anti-infectives</p></div>
<div class="block war drugH1Div" id="F213064"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, fresh intestinal anastomoses, active or latent peptic ulcer, ulcerative colitis [nonspecific]) due to perforation risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Increased mortality was observed in patients receiving high-dose IV methylprednisolone; high-dose corticosteroids should not be used for the management of head injury.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; effects may be enhanced.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with a history of ocular herpes simplex; corneal perforation has occurred; do not use in active ocular herpes simplex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use corticosteroids with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic sclerosis: Use with caution in patients with systemic sclerosis; an increase in scleroderma renal crisis incidence has been observed with corticosteroid use. Monitor BP and renal function in patients with systemic sclerosis treated with corticosteroids (EULAR [Kowal-Bielecka 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults with the smallest possible effective dose for the shortest duration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May affect growth velocity; growth and development should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP ["Inactive" 1997]; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878602"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F213075"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">predniSONE Intensol: 5 mg/mL (30 mL) [contains alcohol, usp; unflavored flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/5 mL (120 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rayos: 1 mg, 2 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Therapy Pack, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (21 ea, 48 ea); 5 mg (21 ea, 48 ea)</p></div>
<div class="block geq drugH1Div" id="F213060"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F213085"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (predniSONE Intensol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $5.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (predniSONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Therapy Pack</b> (predniSONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5MG (21) (per each): $0.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5MG (48) (per each): $0.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG (21) (per each): $1.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10MG (48) (per each): $0.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Rayos Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $110.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $110.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $110.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (predniSONE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.18 - $0.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.16 - $0.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.20 - $0.73</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.19 - $0.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.20 - $1.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.41 - $0.65</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868015"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Winpred: 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 50 mg</p></div>
<div class="block adm drugH1Div" id="F213079"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Administer after meals or with food or milk to decrease GI upset. May administer antacids between meals to help prevent peptic ulcers.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed-release tablets:</i> Swallow whole; do not break, divide, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:8em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet and oral solution formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, minimum necessary dose and duration of prednisone therapy is recommended to minimize risk of GI irritation or ulceration. Proton pump inhibitor therapy is recommended if therapy is to continue chronically.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Oral solution, concentrate:</i> Administer only with provided calibrated dropper.</p></div>
<div class="block admp drugH1Div" id="F52613663"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer after meals or with food or milk to decrease GI upset.</p>
<p style="text-indent:-2em;margin-left:2em;">Delayed-release tablet (Rayos): Swallow whole; do not crush, divide, or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Administer with an accurate measuring device; do not use a household teaspoon (under or overdosage may occur).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral concentrate (Intensol): Administer with the provided calibrated dropper.</p></div>
<div class="block use drugH1Div" id="F213078"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">Anti-inflammatory or immunosuppressant agent in the treatment of a variety of diseases, including allergic (eg, angioedema, contact dermatitis, new-onset urticaria), hematologic (eg, immune thrombocytopenia, warm autoimmune hemolytic anemia), dermatologic, GI, inflammatory, ophthalmic, neoplastic, rheumatic (eg, acute gout flare, vasculitis, dermatomyositis, mixed cryoglobulinemia syndrome, polyarteritis nodosa, polymyositis, polymyalgia rheumatica, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus), autoimmune, nervous system (eg, acute exacerbations of multiple sclerosis), renal, respiratory (eg, asthma), and endocrine (eg, primary or secondary adrenocorticoid deficiency); solid organ rejection (acute/chronic).</p></div>
<div class="block off-label drugH1Div" id="F25471281"><span class="drugH1">Use: Off-Label: Adult</span><p>Alcoholic hepatitis (severe); Bell palsy, new onset; Bullous pemphigoid; Chronic obstructive pulmonary disease, acute exacerbation; COVID-19, hospitalized patients; Duchenne muscular dystrophy; Focal segmental glomerulosclerosis, primary; Giant cell arteritis, treatment; Graft-versus-host disease, acute, treatment; Hepatitis, autoimmune; IgA nephropathy, primary, nonvariant; Minimal change disease, treatment; Multiple myeloma (previously untreated; transplant-ineligible); Myasthenia gravis, acute exacerbation or chronic immunosuppressive therapy; Pericarditis, acute or recurrent; Pneumocystis pneumonia, adjunctive therapy for moderate to severe disease; Prostate cancer, metastatic; Takayasu arteritis; Thyroid eye disease, moderate to severe; Thyroiditis, subacute; Tuberculosis, pulmonary; Urticaria, chronic spontaneous, acute exacerbation</p></div>
<div class="block mst drugH1Div" id="F213155"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">PredniSONE may be confused with methylPREDNISolone, Pramosone, prazosin, prednisoLONE, PriLOSEC, primidone, promethazine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F213138"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F213069"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Abrocitinib.  Management: The use of abrocitinib in combination with other immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: Corticosteroids (Systemic) may diminish the therapeutic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Corticosteroids (Systemic) may enhance the fluid-retaining effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of systemic corticosteroid is reduced. Corticosteroids (Systemic) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Baricitinib.  Management: The use of baricitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Corticosteroids (Systemic) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Corticosteroids (Systemic) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CAR-T Cell Immunotherapy: Corticosteroids (Systemic) may enhance the adverse/toxic effect of CAR-T Cell Immunotherapy. Specifically, the severity and duration of neurologic toxicities may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of CAR-T Cell Immunotherapy.  Management: Avoid use of corticosteroids as premedication before treatment with CAR-T cell immunotherapy agents. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Corticosteroids (Systemic) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing systemic corticosteroids (dosed at 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks) several weeks prior to coccidioides immitis skin antigen testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticorelin: Corticosteroids (Systemic) may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Systemic) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters)<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Corticosteroids (Systemic) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the neuroexcitatory and/or seizure-potentiating effect of PredniSONE. CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of PredniSONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and systemic corticosteroids. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desirudin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Desirudin. More specifically, corticosteroids may increase hemorrhagic risk during desirudin treatment.  Management: Discontinue treatment with systemic corticosteroids prior to desirudin initiation.  If concomitant use cannot be avoided, monitor patients receiving these combinations closely for clinical and laboratory evidence of excessive anticoagulation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Systemic) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Corticosteroids (Systemic). Management: The use of deucravacitinib in combination with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Etrasimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Filgotinib.  Management: Coadministration of filgotinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Ga 68 Dotatate: Corticosteroids (Systemic) may diminish the diagnostic effect of Gallium Ga 68 Dotatate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: PredniSONE may diminish the therapeutic effect of Growth Hormone Analogs. Growth Hormone Analogs may decrease serum concentrations of the active metabolite(s) of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Corticosteroids (Systemic) may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Corticosteroids (Systemic) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).  Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Corticosteroids (Systemic) may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiation of systemic corticosteroids at immunosuppressive doses. Influenza vaccines administered less than 14 days prior to or during such therapy should be repeated 3 months after therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May increase the serum concentration of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lutetium Lu 177 Dotatate: Corticosteroids (Systemic) may diminish the therapeutic effect of Lutetium Lu 177 Dotatate.  Management: Avoid repeated use of high-doses of corticosteroids during treatment with lutetium Lu 177 dotatate. Use of corticosteroids is still permitted for the treatment of neuroendocrine hormonal crisis. The effects of lower corticosteroid doses is unknown.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Corticosteroids (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Corticosteroids (Systemic) may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking systemic corticosteroids.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mifamurtide: Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Corticosteroids (Systemic). MiFEPRIStone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (eg, for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. Management: If concomitant therapy is required, use the lowest dose for the shortest duration to limit the risk of myopathy or neuropathy. Monitor for new onset or worsening muscle weakness, reduction or loss of deep tendon reflexes, and peripheral sensory decriments<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the adverse/toxic effect of Corticosteroids (Systemic). Specifically, the risk of gastrointestinal bleeding, ulceration, and perforation may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ozanimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Corticosteroids (Systemic) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Corticosteroids (Systemic) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Quinolones. Specifically, the risk of tendonitis and tendon rupture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Corticosteroids (Systemic) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: Corticosteroids (Systemic) may enhance the therapeutic effect of Sargramostim. Specifically, corticosteroids may enhance the myeloproliferative effects of sargramostim. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Corticosteroids (Systemic) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing immunosuppressants, such as systemic corticosteroids, prior to initiating sipuleucel-T therapy. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone given for 2 or more weeks are immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Corticosteroids (Systemic) may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Corticosteroids (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Corticosteroids (Systemic) may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Corticosteroids (Systemic) may decrease the serum concentration of Tacrolimus (Systemic). Conversely, when discontinuing corticosteroid therapy, tacrolimus concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Corticosteroids (Systemic) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tesamorelin: May decrease serum concentrations of the active metabolite(s) of PredniSONE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Doses equivalent to more than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks are considered immunosuppressive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Corticosteroids (Systemic) may enhance the immunosuppressive effect of Upadacitinib.  Management: Coadministration of upadacitinib with systemic corticosteroids at doses equivalent to greater than 2 mg/kg or 20 mg/day of prednisone (for persons over 10 kg) administered for 2 or more weeks is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urea Cycle Disorder Agents: Corticosteroids (Systemic) may diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Administer vaccines at least 2 weeks prior to immunosuppressive corticosteroids if possible. If patients are vaccinated less than 14 days prior to or during such therapy, repeat vaccination at least 3 months after therapy if immunocompetence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid live vaccines during and for 1 month after therapy with immunosuppressive doses of corticosteroids (equivalent to prednisone &gt; 2 mg/kg or 20 mg/day in persons over 10 kg for at least 2 weeks). Give live vaccines 4 weeks prior to therapy if possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Corticosteroids (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55463777"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Prednisone is acceptable for use in patients with rheumatic and musculoskeletal diseases who are planning to become pregnant. Doses should be tapered to &lt;20 mg/day with the addition of pregnancy compatible immunosuppressants. Conception should be planned during a period of quiescent/low disease activity. Empiric/prophylactic dose increases of prednisone are not recommended for patients with systemic lupus erythematosus requiring assisted reproductive technology; patients should be monitored and treated if flares occur (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Corticosteroids do not decrease fertility in patients with inflammatory bowel disease (IBD) who wish to become pregnant; however, active IBD may decrease fertility; pregnancy should be planned after a 3- to 6-month remission (Mahadevan 2019).</p></div>
<div class="block pri drugH1Div" id="F213086"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Prednisone and its metabolite, prednisolone, cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">In the mother, prednisone is converted to the active metabolite prednisolone by the liver. Prior to reaching the fetus, prednisolone is converted by placental enzymes back to prednisone. As a result, the level of prednisone remaining in the maternal serum and reaching the fetus are similar; however, the amount of prednisolone reaching the fetus is ~8 to 10 times lower than the maternal serum concentration (healthy women at term) (Beitins 1972).</p>
<p style="text-indent:0em;margin-top:2em;">Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts; however, information is conflicting and may be influenced by maternal dose, duration/frequency of exposure, and indication for use. Additional data are needed to evaluate potential risks of systemic corticosteroids and other adverse pregnancy outcomes (eg, gestational diabetes mellitus, low birth weight, preeclampsia, preterm birth) (ACOG 2019b; Bandoli 2017; Skuladottir 2014). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor infants exposed to prolonged or high doses of prednisone in utero (Saulnier 2010).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, clearance of prednisone may be increased (may be dose dependent) (Ryu 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Prednisone is a preferred oral corticosteroid for the treatment of maternal conditions during pregnancy because placental enzymes limit passage to the embryo (ACOG 2019b).</p>
<p style="text-indent:0em;margin-top:2em;">Prednisone ≤10 mg/day is acceptable for use in pregnant patients with rheumatic and musculoskeletal diseases. Higher doses should be tapered to &lt;20 mg/day with the addition of pregnancy compatible immunosuppressants. Stress dosing is not recommended during vaginal delivery (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Corticosteroids may be used as needed for disease flares in pregnant patients with inflammatory bowel disease; however, maintenance therapy should be avoided (Mahadevan 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events in pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events. Inhaled corticosteroids are recommended for the treatment of asthma during pregnancy; however, systemic corticosteroids, including prednisone, should be used to control acute exacerbations or treat severe persistent asthma. Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).</p>
<p style="text-indent:0em;margin-top:2em;">Prednisone is recommended for use in fetal-neonatal alloimmune thrombocytopenia and pregnancy-associated immune thrombocytopenia (ACOG 2019a; Provan 2019). Prednisone is the preferred immunosuppressant for the treatment of myasthenia gravis in pregnancy (Sanders 2016).</p></div>
<div class="block brc drugH1Div" id="F213087"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Prednisone and its metabolite, prednisolone, are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, prednisolone breast milk concentrations are 5% to 25% of the maternal serum levels, providing a total infant dose &lt;1% of the maternal dose. Actual concentrations are dependent upon maternal dose (Berlin 1979; Katz 1975; Ryu 2018; Sagraves 1981). Peak concentrations of prednisone and prednisolone in breast milk occur ~2 to 3 hours after an oral maternal dose (Berlin 1979; Ryu 2018; Sagraves 1981); the half-life in breast milk is 1.9 hours (prednisone) and 4.2 hours (prednisolone) (Sagraves 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">In a study which included six mother-infant pairs, adverse events were not observed in breastfeeding infants (maternal prednisone dose not provided) (Ito 1993).</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer notes that maternal use of high doses of systemic corticosteroids have the potential to cause adverse events in a breastfeeding infant (eg, growth suppression, interfere with endogenous corticosteroid production); therefore, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. The lowest effective dose should be used to minimize potential infant exposure via breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids are generally considered acceptable in breastfeeding patients when used in usual doses; however, monitoring of the breastfeeding infant is recommended (WHO 2002). Prednisone is one of the oral corticosteroids preferred for use in breastfeeding patients (Butler 2014). Breastfeeding is acceptable for patients with rheumatic and musculoskeletal diseases taking prednisone &lt;20 mg/day (ACR [Sammaritano 2020]). If there is concern about exposure to the infant, some guidelines recommend waiting up to 4 hours after the maternal dose of an oral systemic corticosteroid before breastfeeding in order to decrease potential exposure to the breastfeeding infant (based on a study using prednisolone) (Butler 2014; ERS/TSANZ [Middleton 2020]; Mahadevan 2019; Ost 1985).</p></div>
<div class="block dic drugH1Div" id="F213088"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May require increased dietary intake of pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus; may require decreased dietary intake of sodium and potassium supplementation</p></div>
<div class="block mop drugH1Div" id="F213073"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; weight; serum glucose; electrolytes; creatine kinase; growth in pediatric patients; presence of infection, bone mineral density; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test); Hgb, occult blood loss; chest x-ray (at regular intervals during prolonged therapy); IOP with therapy &gt;6 weeks, eye examination (periodically during therapy [AASLD (Mack 2020)]).</p></div>
<div class="block pha drugH1Div" id="F213063"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system; suppresses adrenal function at high doses. Antitumor effects may be related to inhibition of glucose transport, phosphorylation, or induction of cell death in immature lymphocytes. Antiemetic effects are thought to occur due to blockade of cerebral innervation of the emetic center via inhibition of prostaglandin synthesis.</p></div>
<div class="block phk drugH1Div" id="F213081"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: 50% to 90% (may be altered in hepatic failure, chronic renal failure, inflammatory bowel disease, hyperthyroidism, and in the elderly) (Frey 1990)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding (concentration dependent): &lt;50% (Frey 1990)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to metabolite prednisolone (active)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: Immediate-release tablet: 2 hours; Delayed-release tablet: 6 to 6.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (as conjugates)</p></div>
<div class="block phksp drugH1Div" id="F51220091"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Prednisone is inactive and must be metabolized by the liver to prednisolone. This conversion may be impaired in patients with liver disease; however, prednisolone levels are observed to be higher in patients with severe liver failure than in normal patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F213089"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ultracorten</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Meticorten | Metilpres</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lodotra | Panafcort | Predsone | Sone</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Deltasone | Predimax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Prednicort</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Decortin | Dehydrocortison</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Artinizona | Becortem | Ciclorten | Corticorten | Crispred | Flamacorten | Flamape | Lfm prednisona | Meticorten | Precortil | Predcort | Predicorten | Predinis | Preditec | Prednax | Prednison | Prednisona | Predson | Predval</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dacortin | Prednison Amino | Prednison Axapharm | Prednison galepharm | Prednison spirig hc | Prednison streuli | Prednisone labatec | Ultracorten</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo-prednisone</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bersen | Meticorten | Prednisona | Procion</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Meticorten | Prednisona | Prednisona Genfar</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Prednison | Prednison avmc</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cutason | Decortin | Prednison | Prednison Galen | Prednison hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo Prednisona | Guidonia | Meticorten | Prednisona | Prednisona feltrex | Prednoten</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bersen | Meticorten | Predcor | Prednisona | Presacor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Prednison</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Hostacortin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dacortin | Prednisona alonga | Prednisona cinfa | Prednisona Kern Pharma | Prednisona Pensa | Prednisona tarbis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Di adreson | Me korti | Prednison | Prednison Frederiksberg | Prednison nurison</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cortancyl | Prednisone Almus | Prednisone arrow | Prednisone biogaran | Prednisone cristers | Prednisone Dci | Prednisone eg | Prednisone g gam | Prednisone mylan | Prednisone qualimed | Prednisone ratiopharm | Prednisone Sandoz</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Decortisyl | Delta cortelan | Deltacortone | Di adreson | Econosone | Prednisone cox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-prednisone | Deltasone | Senterlic</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Decortin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dellacorta | Eltazon | Erlanison | Hostacortin | Ifison | Inflason | Nufapredson | Pehacort | Prednison</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Prednitone</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Deltison</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Deltacortene | Prednisone doc generici | Prednisone mylan | Prednisone teva | Soflon | Tuledus</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deltason | Lodotra</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cortancyl | Novo prednisone | Predicor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Decortin | Prednison</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Prednicort</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Prednison</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Cortancyl | Isone | Nisone</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Artrinol On | Cortigen | Donsicol | Ednaprom | Ednapron | Losinon | Meticorten | Norapred | Nosipren | Predicor | Prednisona | Prednisona gi brul | Prednisona landsteiner | Prednisona ultra | Premagnol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Prednison | Prednison Alpharma | Prednison Ratiopharm | Prednison Sandoz | Prednison-GF</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Prednison</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-prednisone | Prednisone clinect</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Antipred | Apo-prenisona | Biocortex | Cortimed | Cortipred | Luxasona | Macroxona | Meticorten | Meticorten sp | Nisacortec | Nisocortec | Nisolan | Nisona | Nisonest | Nisoprex | Pharmapred | Precid | Precorten | Predalen | Predcort | Predimed | Prednibrand | Predniflam | Prednimass | Prednisona | Prednisona- | Prenixin | Presonax | Quillapred | Vercid | Zorzall</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biopred | Biosone | Cort | Derpson | Dli-prednisone | Drazone | Endosone | Oracort | Orasone | Pred | Prednimed | Prednisone gxi | Prednisone organon | Prednisone Westfield | Predoral | Predsone | Prend | Prolix | Qualisone | Steerometz | Systocor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dacortin | Decortin | Encorton | Prednison</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Deltasone | Sterapred</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Cortiol | Meticorten | Prednisona</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Colesol | Corticort | Cortiprex | Monocort p | Prednicort | Prednilasca | Prednisona dallas | Prednisona dasanti | Prednisona dutriec | Prednisona kirei | Prednisona landa | Pregnosin | Zonide</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Prednison</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo prednison</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-prednisone | Deltason</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Deltison</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-prednisone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Prednison | Prednison leciva</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dipred | Isone</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Romezon dr</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alfacort | Dispersona | Prednisona | Pretard</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Meticorten | Prednisona | Prednisona alfa | Vitazon | Zonide</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Farnisone</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Be-tabs prednisone | Meticorten | Panafcort | Predeltin | Pulmison | Trolic</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Panafcort</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-31045947">
<a name="31045947"></a>Adami G, Saag KG. Glucocorticoid-induced osteoporosis update. <i>Curr Opin Rheumatol</i>. 2019;31(4):388-393. doi:10.1097/BOR.0000000000000608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31045947/pubmed" id="31045947" target="_blank">31045947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26320112">
<a name="26320112"></a>Adler Y, Charron P, Imazio M, et al; ESC Scientific Document Group. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J</i>. 2015;36(42):2921-2964. doi: 10.1093/eurheartj/ehv318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26320112/pubmed" id="26320112" target="_blank">26320112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21867553">
<a name="21867553"></a>Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2011;(7):13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21867553/pubmed" id="21867553" target="_blank">21867553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Akahosi.1">
<a name="Akahosi.1"></a>Akahoshi S, Hasegawa Y. Steroid-induced iatrogenic adrenal insufficiency in children: a literature review. <i>Endocrines</i>. 2020;1(2):125-137. doi:10.3390/endocrines1020012</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11205840">
<a name="11205840"></a>Akyüz C, Yariş N, Kutluk MT, Büyükpamukçu M. Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. <i>Pediatr Hematol Oncol</i>. 2001;18(1):47-55. doi:10.1080/088800101750059855<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11205840/pubmed" id="11205840" target="_blank">11205840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-alHashash.2021">
<a name="alHashash.2021"></a>al Hashash J, Regueiro M. Medical management of low-risk adult patients with mild to moderate ulcerative colitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25288693">
<a name="25288693"></a>Allolio B. Extensive expertise in endocrinology. Adrenal crisis. <i>Eur J Endocrinol</i>. 2015;172(3):R115-R124. doi:10.1530/EJE-14-0824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25288693/pubmed" id="25288693" target="_blank">25288693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30801473">
<a name="30801473"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 207: thrombocytopenia in pregnancy. <i>Obstet Gynecol</i>. 2019a;133(3):e181-e193. doi: 10.1097/AOG.0000000000003100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30801473/pubmed" id="30801473" target="_blank">30801473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913201">
<a name="30913201"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion No. 776: immune modulating therapies in pregnancy and lactation. <i>Obstet Gynecol.</i> 2019b;133(4):e287-e295. doi:10.1097/AOG.0000000000003176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30913201/pubmed" id="30913201" target="_blank">30913201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ACR.1">
<a name="ACR.1"></a>American College of Radiology (ACR) Committee on Drugs and Contrast Media. ACR manual on contrast media. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf. Published 2021. Accessed January 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11840435">
<a name="11840435"></a>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. <i>Arthritis Rheum.</i> 2002;46(2):328-346. doi: 10.1002/art.10148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11840435/pubmed" id="11840435" target="_blank">11840435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnold.2022">
<a name="Arnold.2022"></a>Arnold DM. Initial treatment of immune thrombocytopenia (ITP) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.2021">
<a name="Asero.2021"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8246650">
<a name="8246650"></a>Austin JR, Peskind SP, Austin SG, Rice DH. Idiopathic facial nerve paralysis: a randomized double blind controlled study of placebo versus prednisone. <i>Laryngoscope</i>. 1993;103(12):1326-1333. doi: 10.1288/00005537-199312000-00002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8246650/pubmed" id="8246650" target="_blank">8246650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35333779">
<a name="35333779"></a>Bajaj JS, Wong F, Kamath PS, Lai JC, O'Leary JG. Acute-on-chronic liver failure. <i>Am J Gastroenterol</i>. 2022;117(6):831-834. doi:10.14309/ajg.0000000000001748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/35333779/pubmed" id="35333779" target="_blank">35333779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23090580">
<a name="23090580"></a>Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. <i>Curr Diab Rep</i>. 2013;13(1):114-120. doi:10.1007/s11892-012-0339-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23090580/pubmed" id="23090580" target="_blank">23090580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28711148">
<a name="28711148"></a>Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. <i>Rheum Dis Clin North Am.</i> 2017;43(3):489-502. doi:10.1016/j.rdc.2017.04.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28711148/pubmed" id="28711148" target="_blank">28711148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20656187">
<a name="20656187"></a>Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. <i>Transfus Med Rev.</i> 2010;24(3):195-210. doi: 10.1016/j.tmrv.2010.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20656187/pubmed" id="20656187" target="_blank">20656187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34297684">
<a name="34297684"></a>Bartalena L, Kahaly GJ, Baldeschi L, et al; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. <i>Eur J Endocrinol</i>. 2021;185(4):G43-G67. doi:10.1530/EJE-21-0479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34297684/pubmed" id="34297684" target="_blank">34297684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9532337">
<a name="9532337"></a>Bartalena L, Marcocci C, Pinchera A. Treating severe Graves' ophthalmopathy. <i>Baillieres Clin Endocrinol Metab</i>. 1997;11(3):521-536. doi:10.1016/s0950-351x(97)80738-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9532337/pubmed" id="9532337" target="_blank">9532337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24189771">
<a name="24189771"></a>Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. <i>Otolaryngol Head Neck Surg</i>. 2013;149(3)(suppl):S1-S27. doi: 10.1177/0194599813505967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24189771/pubmed" id="24189771" target="_blank">24189771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34140301">
<a name="34140301"></a>Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. <i>Eur Respir J.</i> 2021;58(6):2004079. doi:10.1183/13993003.04079-2020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34140301/pubmed" id="34140301" target="_blank">34140301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5086721">
<a name="5086721"></a>Beitins IZ, Bayard F, Ances IG, et al, “The Transplacental Passage of Prednisone and Prednisolone in Pregnancy Near Term,” <i>J Pediatr</i>, 1972, 81(5):936-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/5086721/pubmed" id="5086721" target="_blank">5086721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27515057">
<a name="27515057"></a>Bellutti Enders F, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. <i>Ann Rheum Dis</i>. 2017;76(2):329-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27515057/pubmed" id="27515057" target="_blank">27515057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11559219">
<a name="11559219"></a>Bennett ML, Fleischer AB Jr, Chamlin SL, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. <i>Arch Dermatol</i>. 2001;137(9):1208-1213. doi:10.1001/archderm.137.9.1208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11559219/pubmed" id="11559219" target="_blank">11559219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23018468">
<a name="23018468"></a>Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. <i>Clin Pharmacokinet</i>. 2012;51(11):711-741. doi:10.1007/s40262-012-0007-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23018468/pubmed" id="23018468" target="_blank">23018468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6880855">
<a name="6880855"></a>Bergrem H. The influence of uremia on pharmacokinetics and protein binding of prednisolone. <i>Acta Med Scand</i>. 1983;213(5):333-337. doi:10.1111/j.0954-6820.1983.tb03747.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/6880855/pubmed" id="6880855" target="_blank">6880855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berlin.1979">
<a name="Berlin.1979"></a>Berlin Jr CM, Kaiser DG, Demers L. Excretion of prednisone and prednisolone in human milk. <i>Pharmacologist</i>. 1979;21:264.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol.</i> 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17982350">
<a name="17982350"></a>Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. <i>Curr Opin Endocrinol Diabetes Obes</i>. 2007;14(6):446-450. doi:10.1097/MED.0b013e3282f15407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17982350/pubmed" id="17982350" target="_blank">17982350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182665">
<a name="18182665"></a>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. <i>J Clin Oncol</i>. 2008;26(2):242-245. doi: 10.1200/JCO.2007.12.4008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18182665/pubmed" id="18182665" target="_blank">18182665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851469">
<a name="22851469"></a>Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.<i> Ann Rheum Dis</i>. 2012;71(11):1771-1782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22851469/pubmed" id="22851469" target="_blank">22851469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bhimraj.2022">
<a name="Bhimraj.2022"></a>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America (IDSA) guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/#toc-5. Updated June 29, 2022. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bird.1">
<a name="Bird.1"></a>Bird SJ. Chronic immunotherapy for myasthenia gravis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 28, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bird.2">
<a name="Bird.2"></a>Bird SJ. Myasthenic crisis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29395989">
<a name="29395989"></a>Birnkrant DJ, Bushby K, Bann CM, et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management [published correction appears in <i>Lancet Neurol. </i>2018;17(6):495]. <i>Lancet Neurol.</i> 2018;17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29395989/pubmed" id="29395989" target="_blank">29395989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4916790">
<a name="4916790"></a>Black DA, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with the nephrotic syndrome. <i>Br Med J</i>. 1970;3(5720):421-426. doi:10.1136/bmj.3.5720.421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/4916790/pubmed" id="4916790" target="_blank">4916790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29530386">
<a name="29530386"></a>Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. <i>Diabetes Res Clin Pract</i>. 2018;139:203-220. doi:10.1016/j.diabres.2018.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29530386/pubmed" id="29530386" target="_blank">29530386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10951436">
<a name="10951436"></a>Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. <i>Muscle Nerve</i>. 2000;23(9):1344-1347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/10951436/pubmed" id="10951436" target="_blank">10951436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7618934">
<a name="7618934"></a>Boot AM, Nauta J, Hokken-Koelega AC, et al, “Renal Transplantation and Osteoporosis,” <i>Arch Dis Child</i>, 1995, 72(6):502-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/7618934/pubmed" id="7618934" target="_blank">7618934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19474430">
<a name="19474430"></a>Bornstein SR. Predisposing factors for adrenal insufficiency. <i>N Engl J Med</i>. 2009;360(22):2328-2339. doi:10.1056/NEJMra0804635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19474430/pubmed" id="19474430" target="_blank">19474430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766904">
<a name="35766904"></a>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2022;36(10):1689-1704. doi:10.1111/jdv.18220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/35766904/pubmed" id="35766904" target="_blank">35766904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8239251">
<a name="8239251"></a>Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. <i>Ann Intern Med</i>. 1993;119(12):1198-1208. doi:10.7326/0003-4819-119-12-199312150-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8239251/pubmed" id="8239251" target="_blank">8239251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26509049">
<a name="26509049"></a>Briot K, Roux C. Glucocorticoid-induced osteoporosis. <i>RMD Open</i>. 2015;1(1):e000014. doi:10.1136/rmdopen-2014-000014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26509049/pubmed" id="26509049" target="_blank">26509049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31412178">
<a name="31412178"></a>Brodsky RA. Warm autoimmune hemolytic anemia. <i>N Engl J Med.</i> 2019;381(7):647-654. doi: 10.1056/NEJMcp1900554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31412178/pubmed" id="31412178" target="_blank">31412178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25844620">
<a name="25844620"></a>Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2015;100(6):2171-2180. doi:10.1210/jc.2015-1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25844620/pubmed" id="25844620" target="_blank">25844620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28585373">
<a name="28585373"></a>Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537. doi:10.1002/art.40137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28585373/pubmed" id="28585373" target="_blank">28585373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30586507">
<a name="30586507"></a>Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. <i>N Engl J Med</i>. 2018;379(26):2547-2556. doi:10.1056/NEJMcp1800214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30586507/pubmed" id="30586507" target="_blank">30586507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36480280">
<a name="36480280"></a>Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. <i>Thyroid</i>. 2022;32(12):1439-1470. doi:10.1089/thy.2022.0251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/36480280/pubmed" id="36480280" target="_blank">36480280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Burman.2022">
<a name="Burman.2022"></a>Burman KD. Subacute thyroiditis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27986133">
<a name="27986133"></a>Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. <i>J Am Acad Dermatol</i>. 2017;76(1):11-16. doi:10.1016/j.jaad.2016.02.1239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27986133/pubmed" id="27986133" target="_blank">27986133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30904473">
<a name="30904473"></a>Castañeda S, García-Castañeda N, Prieto-Peña D, et al. Treatment of polymyalgia rheumatica. <i>Biochem Pharmacol.</i> 2019;165:221-229. doi: 10.1016/j.bcp.2019.03.027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30904473/pubmed" id="30904473" target="_blank">30904473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.2022">
<a name="Cattran.2022"></a>Cattran DC. Focal segmental glomerulosclerosis: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.2023">
<a name="Cattran.2023"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16198208">
<a name="16198208"></a>Chen WX, Wong V. Prognosis of Bell's palsy in children--analysis of 29 cases. <i>Brain Dev</i>. 2005;27(7):504-508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/16198208/pubmed" id="16198208" target="_blank">16198208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22211074">
<a name="22211074"></a>Cheng A. Emergency treatment of anaphylaxis in infants and children.<i> Paediatr Child Health</i>. 2011;16(1):35-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22211074/pubmed" id="22211074" target="_blank">22211074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24347992">
<a name="24347992"></a>Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervous system side effects. <i>J Pharmacol Pharmacother</i>. 2013;4(Suppl 1):S94-S98. doi:10.4103/0976-500X.120975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24347992/pubmed" id="24347992" target="_blank">24347992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3915841">
<a name="3915841"></a>Coggins CH. Adult minimal change nephropathy: experience of the collaborative study of glomerular disease. <i>Trans Am Clin Climatol Assoc</i>. 1986;97:18-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/3915841/pubmed" id="3915841" target="_blank">3915841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohen.1">
<a name="Cohen.1"></a>Cohen RD, Stein AS. Management of moderate to severe ulcerative colitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 25, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohen.2">
<a name="Cohen.2"></a>Cohen S, Mikuls TR. Initial treatment of rheumatoid arthritis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594318">
<a name="12594318"></a>Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. <i>N Engl J Med.</i> 2003;348(8):727-734. doi: 10.1056/NEJMra020529.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/12594318/pubmed" id="12594318" target="_blank">12594318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11779267">
<a name="11779267"></a>Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. <i>JAMA</i>. 2002;287(2):236-240. doi:10.1001/jama.287.2.236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11779267/pubmed" id="11779267" target="_blank">11779267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15634032">
<a name="15634032"></a>Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. <i>Clin Pharmacokinet</i>. 2005;44(1):61-98. doi:10.2165/00003088-200544010-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15634032/pubmed" id="15634032" target="_blank">15634032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21365201">
<a name="21365201"></a>Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. <i>Curr Treat Options Neurol.</i> 2011;13(3):311-323. doi: 10.1007/s11940-011-0119-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21365201/pubmed" id="21365201" target="_blank">21365201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Darras.2020">
<a name="Darras.2020"></a>Darras BT. Duchenne and Becker muscular dystrophy: Glucocorticoid and disease-modifying treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26416931">
<a name="26416931"></a>Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and management of infantile hemangioma.<i> Pediatrics</i>. 2015;136(4):e1060-1104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26416931/pubmed" id="26416931" target="_blank">26416931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20371504">
<a name="20371504"></a>Dasgupta B, Borg FA, Hassan N, et al; BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. <i>Rheumatology (Oxford).</i> 2010;49(8):1594-1597. doi: 10.1093/rheumatology/keq039a.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20371504/pubmed" id="20371504" target="_blank">20371504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24934895">
<a name="24934895"></a>de Almeida JR, Guyatt GH, Sud S, et al; Bell Palsy Working Group, Canadian Society of Otolaryngology - Head and Neck Surgery and Canadian Neurological Sciences Federation. Management of Bell palsy: clinical practice guideline. <i>CMAJ</i>. 2014;186(12):917-922. doi: 10.1503/cmaj.131801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24934895/pubmed" id="24934895" target="_blank">24934895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21612468">
<a name="21612468"></a>de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. <i>N Engl J Med</i>. 2011;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21612468 /pubmed" id="21612468 " target="_blank">21612468 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20888992">
<a name="20888992"></a>de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet</i>. 2010;376(9747):1147-1154. doi: 10.1016/S0140-6736(10)61389-X.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20888992/pubmed" id="20888992" target="_blank">20888992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26359488">
<a name="26359488"></a>Dejaco C, Singh YP, Perel P, et al; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against rheumatism/American College of Rheumatology collaborative initiative. <i>Ann Rheum Dis</i>. 2015;74(10):1799-1807. doi: 10.1136/annrheumdis-2015-207492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26359488/pubmed" id="26359488" target="_blank">26359488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30928086">
<a name="30928086"></a>Delaleu J, Destere A, Hachon L, Declèves X, Lloret-Linares C. Glucocorticoids dosing in obese subjects: a systematic review. <i>Therapie</i>. 2019;74(4):451-458. doi:10.1016/j.therap.2018.11.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30928086/pubmed" id="30928086" target="_blank">30928086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22495399">
<a name="22495399"></a>Della Corte C, Sartorelli MR, Sindoni CD, et al. Autoimmune hepatitis in children: an overview of the disease focusing on current therapies. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(7):739-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22495399/pubmed" id="22495399" target="_blank">22495399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deltasone.1">
<a name="Deltasone.1"></a>Deltasone (prednisone) [prescribing information]. Petaluma, CA: Oculus Innovative Sciences; Received on August 20, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22290637">
<a name="22290637"></a>DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22290637/pubmed" id="22290637" target="_blank">22290637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9464184">
<a name="9464184"></a>Dickerson JE Jr, Dotzel E, Clark AF. Steroid-induced cataract: new perspective from in vitro and lens culture studies. <i>Exp Eye Res</i>. 1997;65(4):507-516. doi:10.1006/exer.1997.0359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9464184/pubmed" id="9464184" target="_blank">9464184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21666852">
<a name="21666852"></a>Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. <i>Expert Rev Clin Pharmacol</i>. 2011;4(2):233-242. doi:10.1586/ecp.11.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21666852/pubmed" id="21666852" target="_blank">21666852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31223468">
<a name="31223468"></a>Dineen R, Thompson CJ, Sherlock M. Adrenal crisis: prevention and management in adult patients. <i>Ther Adv Endocrinol Metab</i>. 2019;10:2042018819848218. doi:10.1177/2042018819848218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31223468/pubmed" id="31223468" target="_blank">31223468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11359498">
<a name="11359498"></a>Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. <i>Dermatol Surg</i>. 2001;27(5):475-485. doi:10.1046/j.1524-4725.2001.00227.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11359498/pubmed" id="11359498" target="_blank">11359498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22241902">
<a name="22241902"></a>Dixon WG, Abrahamowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. <i>Ann Rheum Dis</i>. 2012;71(7):1128-1133. doi:10.1136/annrheumdis-2011-200702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22241902/pubmed" id="22241902" target="_blank">22241902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24943696">
<a name="24943696"></a>Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. <i>Mayo Clin Proc</i>. 2014;89(6):817-834. doi:10.1016/j.mayocp.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24943696/pubmed" id="24943696" target="_blank">24943696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18849193">
<a name="18849193"></a>Engström M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurol.</i> 2008;7(11):993-1000. doi: 10.1016/S1474-4422(08)70221-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18849193/pubmed" id="18849193" target="_blank">18849193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting.<i> Intensive Care Med</i>. 2004;30(1):18-32. doi: 10.1007/s00134-003-2059-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21753160">
<a name="21753160"></a>Escolar DM, Hache LP, Clemens PR, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. <i>Neurology.</i> 2011;77(5):444-452. doi: 10.1212/WNL.0b013e318227b164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21753160/pubmed" id="21753160" target="_blank">21753160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26341719">
<a name="26341719"></a>European Association for the Study of the Liver. EASL Clinical practice guidelines: autoimmune hepatitis [published correction appears in <i>J Hepatol.</i> 2015;63(6):1543-1544]. <i>J Hepatol.</i> 2015;63(4):971-1004. doi: 10.1016/j.jhep.2015.06.030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26341719/pubmed" id="26341719" target="_blank">26341719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17920916">
<a name="17920916"></a>Facon T, Mary JY, Hulin C, et al; Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. <i>Lancet</i>. 2007;370(9594):1209-1218. doi: 10.1016/S0140-6736(07)61537-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17920916/pubmed" id="17920916" target="_blank">17920916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16174762">
<a name="16174762"></a>Facon T, Mary JY, Pégourie B, et al; Intergroupe Francophone du Myélome (IFM) group. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. <i>Blood</i>. 2006;107(4):1292-1298. doi: 10.1182/blood-2005-04-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/16174762/pubmed" id="16174762" target="_blank">16174762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29975414">
<a name="29975414"></a>Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. <i>Cancer</i>. 2018;124(18):3706-3714. doi:10.1002/cncr.31629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29975414/pubmed" id="29975414" target="_blank">29975414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25204470">
<a name="25204470"></a>Fardet L, Fève B. Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. <i>Drugs</i>. 2014;74(15):1731-1745. doi:10.1007/s40265-014-0282-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25204470/pubmed" id="25204470" target="_blank">25204470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25978108">
<a name="25978108"></a>Fardet L, Nazareth I, Petersen I. Synthetic glucocorticoids and early variations of blood pressure: a population-based cohort study. <i>J Clin Endocrinol Metab</i>. 2015;100(7):2777-2783. doi:10.1210/jc.2015-1127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25978108/pubmed" id="25978108" target="_blank">25978108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22764363">
<a name="22764363"></a>Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. <i>Am J Psychiatry</i>. 2012;169(5):491-497. doi:10.1176/appi.ajp.2011.11071009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22764363/pubmed" id="22764363" target="_blank">22764363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2039377">
<a name="2039377"></a>Fenichel GM, Mendell JR, Moxley RT 3rd, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. <i>Arch Neurol</i>. 1991;48(6):575-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/2039377/pubmed" id="2039377" target="_blank">2039377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fervenza.2020">
<a name="Fervenza.2020"></a>Fervenza FC, Leise MD, Roccatello D, Kyle RA. Mixed cryoglobulinemia syndrome: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25641317">
<a name="25641317"></a>Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. <i>Muscle Nerve</i>. 2015;51(5):638-656. doi: 10.1002/mus.24566.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25641317/pubmed" id="25641317" target="_blank">25641317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298665">
<a name="23298665"></a>Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. <i>Diabetes Res Clin Pract</i>. 2013;99(3):277-280. doi:10.1016/j.diabres.2012.12.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23298665/pubmed" id="23298665" target="_blank">23298665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2199128">
<a name="2199128"></a>Frey BM and Frey FJ, “Clinical Pharmacokinetics of Prednisone and Prednisolone,” <i>Clin Pharmacokinet</i>, 1990, 19(2):126-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/2199128/pubmed" id="2199128" target="_blank">2199128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6751835">
<a name="6751835"></a>Frey FJ, Gambertoglio JG, Frey BM, Benet LZ, Amend WJ. Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. <i>Eur J Clin Pharmacol</i>. 1982;23(1):65-74. doi:10.1007/BF01061379<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/6751835/pubmed" id="6751835" target="_blank">6751835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furst.2019">
<a name="Furst.2019"></a>Furst DE, Saag KG. Determinants of glucocorticoid dosing. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 1, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Furst.2019b">
<a name="Furst.2019b"></a>Furst DE, Saag KG. Glucocorticoid withdrawal. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gaffo.2021">
<a name="Gaffo.2021"></a>Gaffo, AL. Treatment of gout flares. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 9, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29752705">
<a name="29752705"></a>Gale S, Wilson JC, Chia J, et al. Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK. <i>Rheumatol Ther</i>. 2018;5(2):327-340. doi:10.1007/s40744-018-0112-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29752705/pubmed" id="29752705" target="_blank">29752705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357821">
<a name="21357821"></a>García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. <i>Circulation</i>. 2011;123(10):1108-1115. doi:10.1161/CIRCULATIONAHA.110.973008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21357821/pubmed" id="21357821" target="_blank">21357821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.2022">
<a name="George.2022"></a>George JN, Mcintosh JJ, Perez Botero J. Thrombocytopenia in pregnancy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32956604">
<a name="32956604"></a>George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. <i>Ann Intern Med</i>. 2020;173(11):870-878. doi:10.7326/M20-1594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/32956604/pubmed" id="32956604" target="_blank">32956604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22187441">
<a name="22187441"></a>Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. <i>Diabetes Care</i>. 2012;35(1):181-188. doi:10.2337/dc11-1230<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22187441/pubmed" id="22187441" target="_blank">22187441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651590">
<a name="19651590"></a>Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19651590/pubmed" id="19651590" target="_blank">19651590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020. Accessed May 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2">
<a name="GINA.2"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis, and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Accessed January 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26833937">
<a name="26833937"></a>Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;86(5):465-472. doi: 10.1212/WNL.0000000000002337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26833937/pubmed" id="26833937" target="_blank">26833937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26795244">
<a name="26795244"></a>Goleva E, Covar R, Martin RJ, Leung DY. Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics. <i>J Allergy Clin Immunol Pract</i>. 2016;4(2):357-360.e2. doi:10.1016/j.jaip.2015.11.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26795244/pubmed" id="26795244" target="_blank">26795244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29611051">
<a name="29611051"></a>González-Gay MA, López-Mejías R, Pina T, Blanco R, Castañeda S. IgA vasculitis: genetics and clinical and therapeutic management. <i>Curr Rheumatol Rep.</i> 2018;20(5):24. doi: 10.1007/s11926-018-0735-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29611051/pubmed" id="29611051" target="_blank">29611051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11868634">
<a name="11868634"></a>Goodall J. Oral corticosteroids for poison ivy dermatitis. <i>CMAJ</i>. 2002;166(3):300-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11868634/pubmed" id="11868634" target="_blank">11868634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24507531">
<a name="24507531"></a>Goodin DS. Glucocorticoid treatment of multiple sclerosis.<i> Handb Clin Neurol.</i> 2014;122:455-464. doi: 10.1016/B978-0-444-52001-2.00020-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24507531/pubmed" id="24507531" target="_blank">24507531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35257507">
<a name="35257507"></a>Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Kawasaki disease. <i>Arthritis Care Res (Hoboken)</i>. 2022;74(4):538-548. doi:10.1002/acr.24838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/35257507/pubmed" id="35257507" target="_blank">35257507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21572374">
<a name="21572374"></a>Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. <i>Plast Reconstr Surg</i>. 2011;128(3):743-752. doi:10.1097/PRS.0b013e3182221398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21572374/pubmed" id="21572374" target="_blank">21572374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23136264">
<a name="23136264"></a>Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2012;79(22):2209-2213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23136264/pubmed" id="23136264" target="_blank">23136264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096556">
<a name="26096556"></a>Grossman A, Messerli FH, Grossman E. Drug induced hypertension--An unappreciated cause of secondary hypertension. <i>Eur J Pharmacol</i>. 2015;763(Pt A):15-22. doi:10.1016/j.ejphar.2015.06.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26096556/pubmed" id="26096556" target="_blank">26096556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11376396">
<a name="11376396"></a>Guin JD. Treatment of toxicodendron dermatitis (poison ivy and poison oak). <i>Skin Therapy Lett</i>. 2001;6(7):3-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11376396/pubmed" id="11376396" target="_blank">11376396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19023528">
<a name="19023528"></a>Gupta P, Bhatia V. Corticosteroid physiology and principles of therapy. <i>Indian J Pediatr</i>. 2008;75(10):1039-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19023528/pubmed" id="19023528" target="_blank">19023528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23919213">
<a name="23919213"></a>Guslandi M. Steroid ulcers: Any news? <i>World J Gastrointest Pharmacol Ther</i>. 2013;4(3):39-40. doi:10.4292/wjgpt.v4.i3.39<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23919213/pubmed" id="23919213" target="_blank">23919213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25785660">
<a name="25785660"></a>Hahn D, Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. <i>Cochrane Database Syst Rev</i>. 2015;2015(3):CD001533.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25785660/pubmed" id="25785660" target="_blank">25785660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hamrahian.2020">
<a name="Hamrahian.2020"></a>Hamrahian AH. The management of the surgical patient taking glucocorticoids. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462474">
<a name="29462474"></a>Haran M, Schattner A, Kozak N, Mate A, Berrebi A, Shvidel L. Acute steroid myopathy: a highly overlooked entity. <i>QJM</i>. 2018;111(5):307-311. doi:10.1093/qjmed/hcy031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29462474/pubmed" id="29462474" target="_blank">29462474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31270110">
<a name="31270110"></a>Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. <i>Ann Rheum Dis.</i> 2020;79(1):19-30<i>
</i><i>.</i><i>
</i>doi: 10.1136/annrheumdis-2019-215672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31270110/pubmed" id="31270110" target="_blank">31270110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heneghan.2022">
<a name="Heneghan.2022"></a>Heneghan MA. Autoimmune hepatitis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11390328">
<a name="11390328"></a>Hernández-Díaz S, Rodríguez LA. Steroids and risk of upper gastrointestinal complications. <i>Am J Epidemiol</i>. 2001;153(11):1089-1093. doi:10.1093/aje/153.11.1089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11390328/pubmed" id="11390328" target="_blank">11390328</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29940960">
<a name="29940960"></a>Hinze CH, Oommen PT, Dressler F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. <i>Pediatr Rheumatol Online J</i>. 2018;16(1):40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29940960/pubmed" id="29940960" target="_blank">29940960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20359588">
<a name="20359588"></a>Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine [published correction appears in <i>J Am Coll Cardiol</i>. 2013;62(11):1039-1040]. <i>J Am Coll Cardiol.</i> 2010;55(14):e27-e129. doi: 10.1016/j.jacc.2010.02.015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20359588/pubmed" id="20359588" target="_blank">20359588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25912994">
<a name="25912994"></a>Hodson EM, Hahn D, Craig JC. Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome. <i>Pediatr Nephrol</i>. 2015;30(7):1043-1046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25912994/pubmed" id="25912994" target="_blank">25912994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23431071">
<a name="23431071"></a>Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. <i>J Am Soc Nephrol.</i> 2013;24(5):702-711. doi: 10.1681/ASN.2012070734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23431071/pubmed" id="23431071" target="_blank">23431071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10835064">
<a name="10835064"></a>Hogg RJ, Portman RJ, Milliner D, et al, “Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),” <i>Pediatrics</i>, 2000, 105(6):1242-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/10835064/pubmed" id="10835064" target="_blank">10835064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25471548">
<a name="25471548"></a>Honoré PM, Jacobs R, De Waele E, et al. What do we know about steroids metabolism and 'PK/PD approach' in AKI and CKD especially while on RRT--current status in 2014. <i>Blood Purif</i>. 2014;38(2):154-157. doi:10.1159/000368390<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25471548/pubmed" id="25471548" target="_blank">25471548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15850848">
<a name="15850848"></a>Hopkins RL, Leinung MC. Exogenous Cushing's syndrome and glucocorticoid withdrawal. <i>Endocrinol Metab Clin North Am</i>. 2005;34(2):371-ix. doi:10.1016/j.ecl.2005.01.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15850848/pubmed" id="15850848" target="_blank">15850848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31094232">
<a name="31094232"></a>Hu K, Adachi JD. Glucocorticoid induced osteoporosis. <i>Expert Rev Endocrinol Metab</i>. 2019;14(4):259-266. doi:10.1080/17446651.2019.1617131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31094232/pubmed" id="31094232" target="_blank">31094232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20191521">
<a name="20191521"></a>Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care Res (Hoboken)</i>. 2010;62(2):219-225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20191521/pubmed" id="20191521" target="_blank">20191521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27803135">
<a name="27803135"></a>Huber AM, Kim S, Reed AM, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. <i>J Rheumatol</i>. 2017;44(1):110-116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27803135/pubmed" id="27803135" target="_blank">27803135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22076847">
<a name="22076847"></a>Huber AM, Robinson AB, Reed AM, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(4):546-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22076847/pubmed" id="22076847" target="_blank">22076847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18684744">
<a name="18684744"></a>Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. <i>Ann Rheum Dis</i>. 2009;68(7):1119-1124. doi:10.1136/ard.2008.092163<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18684744/pubmed" id="18684744" target="_blank">18684744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24330030">
<a name="24330030"></a>Husebye ES, Allolio B, Arlt W, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. <i>J Intern Med</i>. 2014;275(2):104-115. doi:10.1111/joim.12162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24330030/pubmed" id="24330030" target="_blank">24330030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36149449">
<a name="36149449"></a>Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. <i>Eur J Endocrinol</i>. 2022;187(6):G1-G21. doi:10.1530/EJE-22-0689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/36149449/pubmed" id="36149449" target="_blank">36149449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imazio.2022">
<a name="Imazio.2022"></a>Imazio M. Acute pericarditis: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intensol.1">
<a name="Intensol.1"></a>Intensol (prednisone) [prescribing information]. Eatontown, NJ; Hikma Pharmaceuticals USA Inc.; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24141272">
<a name="24141272"></a>Ismail AQ, Alake O, Kallappa C. Do oral steroids aid recovery in children with Bell's palsy?. <i>J Child Neurol</i>. 2014;29(10):NP96-NP97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24141272/pubmed" id="24141272" target="_blank">24141272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al, “Prospective Follow-up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication,” <i>Am J Obstet Gynecol</i>, 1993, 168(5):1393-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081650">
<a name="28081650"></a>James C, Bernstein JA. Current and future therapies for the treatment of histamine-induced angioedema. <i>Expert Opin Pharmacother.</i> 2017;18(3):253-262. doi: 10.1080/14656566.2017.1282461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28081650/pubmed" id="28081650" target="_blank">28081650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17900234">
<a name="17900234"></a>James ER. The etiology of steroid cataract. <i>J Ocul Pharmacol Ther</i>. 2007;23(5):403-420. doi:10.1089/jop.2006.0067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17900234/pubmed" id="17900234" target="_blank">17900234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31656440">
<a name="31656440"></a>Janes M, Kuster S, Goldson TM, Forjuoh SN. Steroid-induced psychosis. <i>Proc (Bayl Univ Med Cent)</i>. 2019;32(4):614-615. doi:10.1080/08998280.2019.1629223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31656440/pubmed" id="31656440" target="_blank">31656440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23546607">
<a name="23546607"></a>Johannesdottir SA, Horváth-Puhó E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. <i>JAMA Intern Med</i>. 2013;173(9):743-752. doi:10.1001/jamainternmed.2013.122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23546607/pubmed" id="23546607" target="_blank">23546607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821508">
<a name="11821508"></a>Joly P, Roujeau JC, Benichou J, et al; Bullous Diseases French Study Group. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. <i>N Engl J Med.</i> 2002;346(5):321-327. doi:10.1056/NEJMoa011592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11821508/pubmed" id="11821508" target="_blank">11821508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27105755">
<a name="27105755"></a>Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. <i>Semin Arthritis Rheum</i>. 2016;46(1):133-141. doi:10.1016/j.semarthrit.2016.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27105755/pubmed" id="27105755" target="_blank">27105755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15998777">
<a name="15998777"></a>Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. <i>J Clin Endocrinol Metab</i>. 2005;90(9):5234-5240. doi:10.1210/jc.2005-0148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15998777/pubmed" id="15998777" target="_blank">15998777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1186783">
<a name="1186783"></a>Katz FH and Duncan BR, "Letter: Entry of Prednisone Into Human Milk,"<i> N Engl J Med</i>, 1975, 293(22):1154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/1186783/pubmed" id="1186783" target="_blank">1186783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21079154">
<a name="21079154"></a>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21079154/pubmed" id="21079154" target="_blank">21079154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2020">
<a name="Khan.2020"></a>Khan DA. Chronic spontaneous urticaria: Standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024029">
<a name="23024029"></a>Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology (ACR). 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1447-1461. doi:10.1002/acr.21773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23024029/pubmed" id="23024029" target="_blank">23024029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for Glomerulonephritis. <i>Kidney International Supplements</i>. June 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney</i>
<i>Int</i>. 2021;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23871408">
<a name="23871408"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23871408/pubmed" id="23871408" target="_blank">23871408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28077146">
<a name="28077146"></a>Kim S, Kahn P, Robinson AB, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. <i>Pediatr Rheumatol Online J</i>. 2017;15(1):1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28077146/pubmed" id="28077146" target="_blank">28077146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485648">
<a name="17485648"></a>King WM, Ruttencutter R, Nagaraja HN, et al. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. <i>Neurology</i>. 2007;68(19):1607-1613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17485648/pubmed" id="17485648" target="_blank">17485648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20927731">
<a name="20927731"></a>Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. <i>Cochrane Database Syst Rev.</i> 2010;2010(10):CD002292. doi:10.1002/14651858.CD002292.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20927731/pubmed" id="20927731" target="_blank">20927731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2020">
<a name="Kliegman.2020"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22405251">
<a name="22405251"></a>Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. <i>Lancet</i>. 2012;379(9826):1613-1620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22405251/pubmed" id="22405251" target="_blank">22405251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis</i>. 2017;76(8):1327-1339. doi: 10.1136/annrheumdis-2016-209909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30584062">
<a name="30584062"></a>Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. <i>Pediatrics</i>. 2019;143(1):e20183475. doi:10.1542/peds.2018-3475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30584062/pubmed" id="30584062" target="_blank">30584062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16377829">
<a name="16377829"></a>Lacomis D. Myasthenic crisis. <i>Neurocrit Care.</i> 2005;3(3):189-194. doi: 10.1385/NCC:3:3:189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/16377829/pubmed" id="16377829" target="_blank">16377829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15932528">
<a name="15932528"></a>Lam DS, Fan DS, Ng JS, et al, "Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial," <i>Clin Experiment Ophthalmol</i>, 2005, 33(3):252-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15932528/pubmed" id="15932528" target="_blank">15932528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26289063">
<a name="26289063"></a>Larkins N, Kim S, Craig J, Hodson E. Steroid-sensitive nephrotic syndrome: an evidence-based update of immunosuppressive treatment in children. <i>Arch Dis Child</i>. 2016;101(4):404-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26289063/pubmed" id="26289063" target="_blank">26289063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17332238">
<a name="17332238"></a>Leonard MB, "Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease," <i>Pediatrics</i>, 2007, 119 Suppl 2:S166-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17332238/pubmed" id="17332238" target="_blank">17332238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LeWinter.1">
<a name="LeWinter.1"></a>LeWinter MM. Pericardial complications of myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults [published correction appears in <i>Am J Gastroenterol</i>. 2018;113(7):1101]. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26505932">
<a name="26505932"></a>Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol.</i> 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26505932/pubmed" id="26505932" target="_blank">26505932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23947590">
<a name="23947590"></a>Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. <i>Allergy Asthma Clin Immunol</i>. 2013;9(1):30. doi:10.1186/1710-1492-9-30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23947590/pubmed" id="23947590" target="_blank">23947590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17504884">
<a name="17504884"></a>Loddenkemper T, Sharma P, Katzan I, Plant GT. Risk factors for early visual deterioration in temporal arteritis. <i>J Neurol Neurosurg Psychiatry.</i> 2007;78(11):1255-1259. doi: 10.1136/jnnp.2006.113787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17504884/pubmed" id="17504884" target="_blank">17504884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20186367">
<a name="20186367"></a>Lougheed MD, Lemière C, Dell SD, et al, “Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,” <i>Can Respir J</i>, 2010, 17(1):15-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20186367/pubmed" id="20186367" target="_blank">20186367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al, "Use of Glucocorticoids in Pregnancy,"<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579642">
<a name="35579642"></a>Lv J, Wong MG, Hladunewich MA, et al; TESTING Study Group. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. <i>JAMA</i>. 2022;327(19):1888-1898. doi:10.1001/jama.2022.5368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/35579642/pubmed" id="35579642" target="_blank">35579642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18930568">
<a name="18930568"></a>Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. <i>Am J Kidney Dis</i>. 2009;53(1):26-32. doi:10.1053/j.ajkd.2008.07.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18930568/pubmed" id="18930568" target="_blank">18930568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31863477">
<a name="31863477"></a>Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2020;72(2):671-722. doi:10.1002/hep.31065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31863477/pubmed" id="31863477" target="_blank">31863477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658060">
<a name="30658060"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Gastroenterology</i>. 2019;156(5):1508-1524. doi:10.1053/j.gastro.2018.12.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30658060/pubmed" id="30658060" target="_blank">30658060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19628647">
<a name="19628647"></a>Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. <i>Nephrol Dial Transplant</i>. 2009;24(12):3694-3701. doi:10.1093/ndt/gfp356<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19628647/pubmed" id="19628647" target="_blank">19628647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11502779">
<a name="11502779"></a>Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.<i> J Clin Endocrinol Metab</i>. 2001;86(8):3562-3567. doi:10.1210/jcem.86.8.7737<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/11502779/pubmed" id="11502779" target="_blank">11502779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18436445">
<a name="18436445"></a>Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. <i>Neuromuscul Disord</i>. 2008;18(5):365-370. doi: 10.1016/j.nmd.2008.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18436445/pubmed" id="18436445" target="_blank">18436445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22510384">
<a name="22510384"></a>Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.<i> Biol Blood Marrow Transplant.</i> 2012;18(8):1150-1163. doi: 10.1016/j.bbmt.2012.04.005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22510384/pubmed" id="22510384" target="_blank">22510384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23465020">
<a name="23465020"></a>Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. <i>Am J Transplant.</i> 2013;(13)(suppl 4):272-279. doi: 10.1111/ajt.12119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23465020/pubmed" id="23465020" target="_blank">23465020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29231133">
<a name="29231133"></a>Mateos MV, Dimopoulos MA, Cavo M, et al; ALCYONE Trial Investigators. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. <i>N Engl J Med</i>. 2018;378(6):518-528. doi: 10.1056/NEJMoa1714678.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29231133/pubmed" id="29231133" target="_blank">29231133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27149418">
<a name="27149418"></a>Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. <i>Cochrane Database Syst Rev</i>. 2016;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27149418/pubmed" id="27149418" target="_blank">27149418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235884">
<a name="34235884"></a>Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and takayasu arteritis. <i>Arthritis Rheumatol.</i> 2021;73(8):1349-1365. doi:10.1002/art.41774<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34235884/pubmed" id="34235884" target="_blank">34235884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32392512">
<a name="32392512"></a>Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. <i>CMAJ</i>. 2020;192(12):E295-E301. doi:10.1503/cmaj.191012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/32392512/pubmed" id="32392512" target="_blank">32392512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30428290">
<a name="30428290"></a>Meintjes G, Stek C, Blumenthal L, et al; PredART Trial Team. Prednisone for the prevention of paradoxical tuberculosis-associated IRIS.<i> N Engl J Med</i>. 2018;379(20):1915-1925. doi: 10.1056/NEJMoa1800762.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30428290/pubmed" id="30428290" target="_blank">30428290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2657428">
<a name="2657428"></a>Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. <i>N Engl J Med</i>. 1989;320(24):1592-1597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/2657428/pubmed" id="2657428" target="_blank">2657428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.2020">
<a name="Merkel.2020"></a>Merkel PA. Treatment of Takayasu arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890993">
<a name="10890993"></a>Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. <i>Arch Dermatol</i>. 2000;136(7):905-914. doi:10.1001/archderm.136.7.905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/10890993/pubmed" id="10890993" target="_blank">10890993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29356770">
<a name="29356770"></a>Mieli-Vergani G, Vergani D, Baumann U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee Position Statement. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(2):345-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29356770/pubmed" id="29356770" target="_blank">29356770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23982055">
<a name="23982055"></a>Migita K, Sasaki Y, Ishizuka N, et al. Glucocorticoid therapy and the risk of infection in patients with newly diagnosed autoimmune disease. <i>Medicine (Baltimore)</i>. 2013;92(5):285-293. doi:10.1097/MD.0b013e3182a72299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23982055/pubmed" id="23982055" target="_blank">23982055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30932732">
<a name="30932732"></a>Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. <i>J Clin Oncol.</i> 2019;37(14):1228-1263. doi:10.1200/JCO.18.02096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30932732/pubmed" id="30932732" target="_blank">30932732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6499362">
<a name="6499362"></a>Milsap RL, Plaisance KI, Jusko WJ. Prednisolone disposition in obese men. <i>Clin Pharmacol Ther</i>. 1984;36(6):824-831. doi:10.1038/clpt.1984.263<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/6499362/pubmed" id="6499362" target="_blank">6499362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162255">
<a name="22162255"></a>Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(3):375-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22162255/pubmed" id="22162255" target="_blank">22162255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15452302">
<a name="15452302"></a>Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. <i>Neurology</i>. 2004;63(6):1079-1080. doi: 10.1212/01.wnl.0000138572.82125.f5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15452302/pubmed" id="15452302" target="_blank">15452302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15642897">
<a name="15642897"></a>Moxley RT 3rd, Ashwal S, Pandya S, et al, “Practice Parameter: Corticosteroid Treatment of Duchenne Dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,” <i>Neurology</i>, 2005, 64(1):13-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15642897/pubmed" id="15642897" target="_blank">15642897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799164">
<a name="27799164"></a>Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. <i>Blood</i>. 2017;129(3):289-298. doi: 10.1182/blood-2016-09-719773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27799164/pubmed" id="27799164" target="_blank">27799164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24909803">
<a name="24909803"></a>Muraro A, Roberts G, Worm M, et al; EAACI Food Allergy and Anaphylaxis Guidelines Group. Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. <i>Allergy</i>. 2014;69(8):1026-1045. doi: 10.1111/all.12437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24909803/pubmed" id="24909803" target="_blank">24909803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16513709">
<a name="16513709"></a>Murray TJ. Diagnosis and treatment of multiple sclerosis. <i>BMJ</i>. 2006;332(7540):525-527. doi: 10.1136/bmj.332.7540.525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/16513709/pubmed" id="16513709" target="_blank">16513709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4121073">
<a name="4121073"></a>Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. <i>Lancet</i>. 1973;1(7806):735-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/4121073/pubmed" id="4121073" target="_blank">4121073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murrell.2023">
<a name="Murrell.2023"></a>Murrell DF, Ramirez-Quizon M. Management and prognosis of bullous pemphigoid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/management-and-prognosis-of-bullous-pemphigoid?search=bullous%20pemphigoid&amp;source=search_result&amp;selectedTitle=1~148&amp;usage_type=default&amp;display_rank=1#H2181224722" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19566504">
<a name="19566504"></a>Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. <i>Acta Neurol Scand Suppl.</i> 2009;(189):73-80. doi: 10.1111/j.1600-0404.2009.01213.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19566504/pubmed" id="19566504" target="_blank">19566504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27012010">
<a name="27012010"></a>Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27012010/pubmed" id="27012010" target="_blank">27012010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24833682">
<a name="24833682"></a>Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. <i>BMJ Open</i>. 2014;4(5):e004587. doi:10.1136/bmjopen-2013-004587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24833682/pubmed" id="24833682" target="_blank">24833682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.1">
<a name="NAEPP.1"></a>National Asthma Education and Prevention Program (NAEPP). <i>Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma</i>. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf" target="_blank">https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthgdln_1.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.2022">
<a name="NIH.2022"></a>National Institutes of Health (NIH). Coronavirus disease (COVID-19) treatment guidelines: Therapeutic management of patients with COVID-19. <a href="https://www.covid19treatmentguidelines.nih.gov/therapeutic-management" target="_blank">https://www.covid19treatmentguidelines.nih.gov/therapeutic-management</a>. Updated September 26, 2022. Accessed September 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31794604">
<a name="31794604"></a>Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(23):3829-3866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31794604/pubmed" id="31794604" target="_blank">31794604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15253942">
<a name="15253942"></a>Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. <i>Heart</i>. 2004;90(8):829-830. doi:10.1136/hrt.2003.031492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15253942/pubmed" id="15253942" target="_blank">15253942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905379">
<a name="25905379"></a>Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP. Glucocorticoid therapy and adrenal suppression. In: Feingold KR, Anawalt B, Boyce A, et al., eds. <i>Endotext</i>. MDText.com, Inc.; October 19, 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25905379/pubmed" id="25905379" target="_blank">25905379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nieman.2020">
<a name="Nieman.2020"></a>Nieman LK. Treatment of adrenal insufficiency in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 14, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ODell.2020">
<a name="ODell.2020"></a>O'Dell JR. Use of glucocorticoids in the treatment of rheumatoid arthritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 5, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23256914">
<a name="23256914"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2013;61(4):e78-e140. doi:10.1016/j.jacc.2012.11.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23256914/pubmed" id="23256914" target="_blank">23256914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Olek.2021">
<a name="Olek.2021"></a>Olek MJ, Howard J. Treatment of acute exacerbations of multiple sclerosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3998938">
<a name="3998938"></a>Ost L, Wettrell G, Bjorkhem I, et al, "Prednisolone Excretion in Human Milk," <i>J Pediatr</i>, 1985, 106(6):1008-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/3998938/pubmed" id="3998938" target="_blank">3998938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22015886">
<a name="22015886"></a>Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. <i>Obstet Gynecol</i>. 2011;118(5):1157-1163. doi: 10.1097/AOG.0b013e31823403f4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22015886/pubmed" id="22015886" target="_blank">22015886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9596297">
<a name="9596297"></a>Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. <i>Chest.</i> 1998;113(5):1215-1224. doi: 10.1378/chest.113.5.1215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9596297/pubmed" id="9596297" target="_blank">9596297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910822">
<a name="24910822"></a>Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. <i>Indian J Endocrinol Metab</i>. 2013;17(Suppl 3):S612-S617. doi:10.4103/2230-8210.123548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24910822/pubmed" id="24910822" target="_blank">24910822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33923971">
<a name="33923971"></a>Pelewicz K, Miśkiewicz P. Glucocorticoid withdrawal—an overview on when and how to diagnose adrenal insufficiency in clinical practice. <i>Diagnostics (Basel)</i>. 2021;11(4):728. doi:10.3390/diagnostics11040728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/33923971/pubmed" id="33923971" target="_blank">33923971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36884258">
<a name="36884258"></a>Percik R, Criseno S, Adam S, et al. Diagnostic criteria and management recommendations for immune related endocrinopathies following immune checkpoint inhibitor therapy for cancer. <i>Endocr Connect</i>. Published online March 1, 2023. doi:10.1530/EC-22-0513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/36884258/pubmed" id="36884258" target="_blank">36884258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20471889">
<a name="20471889"></a>Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. <i>Joint Bone Spine</i>. 2011;78(1):41-44. doi:10.1016/j.jbspin.2010.02.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20471889/pubmed" id="20471889" target="_blank">20471889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924342">
<a name="28924342"></a>Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: An avoidable irreversible blindness. <i>J Curr Glaucoma Pract</i>. 2017;11(2):67-72. doi:10.5005/jp-journals-l0028-1226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28924342/pubmed" id="28924342" target="_blank">28924342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21303705">
<a name="21303705"></a>Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmun Rev.</i> 2011;10(8):444-454. doi: 10.1016/j.autrev.2011.01.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21303705/pubmed" id="21303705" target="_blank">21303705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503409">
<a name="22503409"></a>Pitaro J, Waissbluth S, Daniel SJ. Do children with Bell's palsy benefit from steroid treatment? A systematic review. <i>Int J Pediatr Otorhinolaryngol</i>. 2012;76(7):921-926.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22503409/pubmed" id="22503409" target="_blank">22503409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27177728">
<a name="27177728"></a>Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes Endocrinol</i>. 2016;4(7):611-629. doi:10.1016/S2213-8587(16)00086-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27177728/pubmed" id="27177728" target="_blank">27177728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9542620">
<a name="9542620"></a>Polosa R, Prosperini G, Pintaldi L, Rey JP, Colombrita R. Anaphylaxis after prednisone. <i>Allergy</i>. 1998;53(3):330-331. doi:10.1111/j.1398-9995.1998.tb03900.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9542620/pubmed" id="9542620" target="_blank">9542620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy.</i> 2015;45(3):547-565. doi:10.1111/cea.12494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10093981">
<a name="10093981"></a>Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. <i>Lancet</i>. 1999;353(9156):883-887. doi:10.1016/s0140-6736(98)03563-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/10093981/pubmed" id="10093981" target="_blank">10093981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lannett.1">
<a name="Lannett.1"></a>Prednisone tablet [prescribing information]. Philadelphia, PA: Lannett Company, Inc; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AvKARE.1">
<a name="AvKARE.1"></a>Prednisone tablet [prescribing information]. Pulaski, TN: AvKARE; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-West-Ward.1">
<a name="West-Ward.1"></a>Prednisone tablet, solution, solution concentrate [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; March 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34253540">
<a name="34253540"></a>Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. <i>BMJ</i>. 2021;374:n1380. doi:10.1136/bmj.n1380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34253540/pubmed" id="34253540" target="_blank">34253540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prok.2022">
<a name="Prok.2022"></a>Prok L, McGovern T. Poison ivy (Toxicodendron) dermatitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31770441">
<a name="31770441"></a>Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood Adv</i>. 2019;3(22):3780-3817. doi:10.1182/bloodadvances.2019000812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31770441/pubmed" id="31770441" target="_blank">31770441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27802508">
<a name="27802508"></a>Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians (ACP). Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. <i>Ann Intern Med.</i> 2017;166(1):58-68. doi: 10.7326/M16-0570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27802508/pubmed" id="27802508" target="_blank">27802508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rayos.2019">
<a name="Rayos.2019"></a>Rayos (prednisone) [prescribing information]. Lake Forest, IL; Horizon Therapeutics USA Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757964">
<a name="21757964"></a>Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. <i>Ophthalmic Res</i>. 2012;47(2):66-80. doi:10.1159/000328630<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21757964/pubmed" id="21757964" target="_blank">21757964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Regueiro.2022">
<a name="Regueiro.2022"></a>Regueiro M, Al Hashash J. Overview of the medical management of mild (low risk) Crohn disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8129444">
<a name="8129444"></a>Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, “Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,” <i>Arch Dis Child</i>, 1994, 70(2):151-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8129444/pubmed" id="8129444" target="_blank">8129444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29741130">
<a name="29741130"></a>Rice JB, White AG, Johnson M, et al. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. <i>Curr Med Res Opin</i>. 2018;34(8):1519-1527. doi:10.1080/03007995.2018.1474090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29741130/pubmed" id="29741130" target="_blank">29741130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27457514">
<a name="27457514"></a>Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi:10.1136/annrheumdis-2016-209707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27457514/pubmed" id="27457514" target="_blank">27457514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31021516">
<a name="31021516"></a>Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. <i>Arthritis Care Res (Hoboken)</i>. 2019;71(6):717-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/31021516/pubmed" id="31021516" target="_blank">31021516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339215">
<a name="24339215"></a>Ringold S, Weiss PF, Colbert RA, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2014;66(7):1063-1072.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24339215/pubmed" id="24339215" target="_blank">24339215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ronthal.2020">
<a name="Ronthal.2020"></a>Ronthal M. Bell's palsy: treatment and prognosis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 11, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis [published correction appears in <i>Thyroid</i>. 2017;27(11):1462]. <i>Thyroid</i>. 2016;26(10):1343-1421. doi 10.1089/thy.2016.0229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26034636">
<a name="26034636"></a>Roth P, Happold C, Weller M. Corticosteroid use in neuro-oncology: an update. <i>Neurooncol Pract</i>. 2015;2(1):6-12. doi:10.1093/nop/npu029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26034636/pubmed" id="26034636" target="_blank">26034636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24847759">
<a name="24847759"></a>Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.<i> Am J Hematol.</i> 2014;89(9):E150-E155. doi: 10.1002/ajh.23767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24847759/pubmed" id="24847759" target="_blank">24847759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23157995">
<a name="23157995"></a>Roxanas MG, Hunt GE. Rapid reversal of corticosteroid-induced mania with sodium valproate: a case series of 20 patients. <i>Psychosomatics</i>. 2012;53(6):575-581. doi:10.1016/j.psym.2012.06.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23157995/pubmed" id="23157995" target="_blank">23157995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30840605">
<a name="30840605"></a>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <i>Am J Gastroenterol.</i> 2019;114(3):384-413. doi: 10.14309/ajg.0000000000000152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30840605/pubmed" id="30840605" target="_blank">30840605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516861">
<a name="22516861"></a>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22516861/pubmed" id="22516861" target="_blank">22516861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892326">
<a name="23892326"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice [published correction appears in <i>Bone Marrow Transplant.</i> 2014;49(2):319]. <i>Bone Marrow Transplant.</i> 2014;49(2):168-173. doi: 10.1038/bmt.2013.107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23892326/pubmed" id="23892326" target="_blank">23892326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25601341">
<a name="25601341"></a>Ryan CJ, Smith MR, Fizazi K, et al; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncol</i>. 2015;16(2):152-160. doi: 10.1016/S1470-2045(14)71205-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25601341/pubmed" id="25601341" target="_blank">25601341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29733485">
<a name="29733485"></a>Ryu RJ, Easterling TR, Caritis SN, et al. Prednisone pharmacokinetics during pregnancy and lactation. <i>J Clin Pharmacol</i>. 2018;58(9):1223-1232. doi:10.1002/jcph.1122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29733485/pubmed" id="29733485" target="_blank">29733485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8551406">
<a name="8551406"></a>Sadan N, Wolach B. Treatment of hemangiomas of infants with high doses of prednisone. <i>J Pediatr</i>. 1996;128(1):141-146. doi:10.1016/s0022-3476(96)70446-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8551406/pubmed" id="8551406" target="_blank">8551406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sagraves.1981">
<a name="Sagraves.1981"></a>Sagraves R, Kaiser D, and Sharpe GL, “Prednisone and Prednisolone Concentrations in the Milk of a Lactating Mother,” <i>Drug Intell Clin Pharm</i>, 1981, 15:484.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8161268">
<a name="8161268"></a>Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. <i>Ann Surg</i>. 1994;219(4):416-425. doi:10.1097/00000658-199404000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8161268/pubmed" id="8161268" target="_blank">8161268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salvarani.1">
<a name="Salvarani.1"></a>Salvarani C, Muratore F. Treatment of giant cell arteritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Salvarani.2021">
<a name="Salvarani.2021"></a>Salvarani C, Muratore F. Treatment of polymyalgia rheumatica. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol.</i> 2020;72(4):529-556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27358333">
<a name="27358333"></a>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. <i>Neurology</i>. 2016;87(4):419-425. doi:10.1212/WNL.0000000000002790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27358333/pubmed" id="27358333" target="_blank">27358333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20081543">
<a name="20081543"></a>Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.<i> J Pediatr Gastroenterol Nutr</i>. 2010;(50 Suppl 1):S1-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/20081543/pubmed" id="20081543" target="_blank">20081543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18753647">
<a name="18753647"></a>San Miguel JF, Schlag R, Khuageva NK, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. <i>N Engl J Med</i>. 2008;359(9):906-917. doi: 10.1056/NEJMoa0801479.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18753647/pubmed" id="18753647" target="_blank">18753647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7576399">
<a name="7576399"></a>Sato A, Funder JW, Okubo M, Kubota E, Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. <i>Am J Hypertens</i>. 1995;8(8):823-828. doi:10.1016/0895-7061(95)00149-J<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/7576399/pubmed" id="7576399" target="_blank">7576399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19902248">
<a name="19902248"></a>Saulnier PJ, Piguel X, Perault-Pochat MC, Csizmadia-Bremaud C, Saulnier JP. Hypoglycaemic seizure and neonatal acute adrenal insufficiency after maternal exposure to prednisone during pregnancy: a case report. <i>Eur J Pediatr</i>. 2010;169(6):763-765. doi:10.1007/s00431-009-1095-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19902248/pubmed" id="19902248" target="_blank">19902248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sax.2020">
<a name="Sax.2020"></a>Sax PE. Treatment and prevention of Pneumocystis infection in patients with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23352781">
<a name="23352781"></a>Schram G, Fournier A, Leduc H, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. <i>J Am Coll Cardiol.</i> 2013;61:948–954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23352781/pubmed" id="23352781" target="_blank">23352781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32001253">
<a name="32001253"></a>Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. <i>J Allergy Clin Immunol.</i> 2020;145(4):1082-1123. doi:10.1016/j.jaci.2020.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/32001253/pubmed" id="32001253" target="_blank">32001253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10787466">
<a name="10787466"></a>Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. <i>Can J Cardiol</i>. 2000;16(4):505-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/10787466/pubmed" id="10787466" target="_blank">10787466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777675">
<a name="24777675"></a>Skuladottir H, Wilcox AJ, Ma C, et al. Corticosteroid use and risk of orofacial clefts. <i>Birth Defects Res A Clin Mol Teratol.</i> 2014;100(6):499-506. doi:10.1002/bdra.23248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/24777675/pubmed" id="24777675" target="_blank">24777675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4538724">
<a name="4538724"></a>Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. <i>Gastroenterology</i>. 1972;63(5):820-833.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/4538724/pubmed" id="4538724" target="_blank">4538724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15253953">
<a name="15253953"></a>Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. <i>Heart</i>. 2004;90(8):859-865. doi:10.1136/hrt.2003.020180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15253953/pubmed" id="15253953" target="_blank">15253953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi: 10.1210/jc.2018-01865.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9751093">
<a name="9751093"></a>Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. <i>Arthritis Rheum</i>. 1998;41(9):1613-1619. doi: 10.1002/1529-0131(199809)41:9&lt;1613::AID-ART11&gt;3.0.CO;2-O.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/9751093/pubmed" id="9751093" target="_blank">9751093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15879445">
<a name="15879445"></a>Stirling CM, Mathieson P, Boulton-Jones JM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. <i>QJM</i>. 2005;98(6):443-449. doi:10.1093/qjmed/hci072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15879445/pubmed" id="15879445" target="_blank">15879445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stoller.1">
<a name="Stoller.1"></a>Stoller JK. COPD exacerbations: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 31, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18256860">
<a name="18256860"></a>Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. <i>Support Care Cancer</i>. 2008;16(9):1041-1048. doi:10.1007/s00520-007-0395-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/18256860/pubmed" id="18256860" target="_blank">18256860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240704">
<a name="26240704"></a>Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. <i>World J Diabetes</i>. 2015;6(8):1073-1081. doi:10.4239/wjd.v6.i8.1073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26240704/pubmed" id="26240704" target="_blank">26240704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21523923">
<a name="21523923"></a>Tarabishy AB, Ahn E, Mandell BF, Lowder CY. Central serous retinopathy. <i>Arthritis Care Res (Hoboken)</i>. 2011;63(8):1075-1082. doi:10.1002/acr.20485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21523923/pubmed" id="21523923" target="_blank">21523923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Targoff.2022">
<a name="Targoff.2022"></a>Targoff IN. Initial treatment of dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15470213">
<a name="15470213"></a>Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. <i>N Engl J Med</i>. 2004;351(15):1502-1512.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15470213/pubmed" id="15470213" target="_blank">15470213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thomas.2019">
<a name="Thomas.2019"></a>Thomas CF Jr, Limper AH. Treatment and prevention of Pneumocystis infection in patients without HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21132302">
<a name="21132302"></a>Trang G, Steele R, Baron M, Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatol Int</i>. 2012;32(3):645-653. doi: 10.1007/s00296-010-1697-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/21132302/pubmed" id="21132302" target="_blank">21132302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8348508">
<a name="8348508"></a>Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. <i>Cancer</i>. 1993;72(5):1779-1783. doi:10.1002/1097-0142(19930901)72:5&lt;1779::aid-cncr2820720543&gt;3.0.co;2-m<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8348508/pubmed" id="8348508" target="_blank">8348508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15716334">
<a name="15716334"></a>Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. <i>J Am Soc Nephrol</i>. 2005;16(4):1061-1068. doi:10.1681/ASN.2004070593<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15716334/pubmed" id="15716334" target="_blank">15716334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096497">
<a name="26096497"></a>Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. <i>Aliment Pharmacol Ther</i>. 2015;42(5):599-606. doi:10.1111/apt.13298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26096497/pubmed" id="26096497" target="_blank">26096497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3541262">
<a name="3541262"></a>Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. <i>Surv Ophthalmol</i>. 1986;31(2):102-110. doi:10.1016/0039-6257(86)90077-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/3541262/pubmed" id="3541262" target="_blank">3541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines</a>. Updated August 18, 2020. Accessed March 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>.Updated December 9, 2019. Accessed March 8, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16682576">
<a name="16682576"></a>van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. <i>Arch Intern Med</i>. 2006;166(9):1016-1020. doi:10.1001/archinte.166.9.1016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/16682576/pubmed" id="16682576" target="_blank">16682576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33026087">
<a name="33026087"></a>van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. <i>J Crohns Colitis</i>. Published online October 7, 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/33026087/pubmed" id="33026087" target="_blank">33026087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12733732">
<a name="12733732"></a>van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. <i>J Bone Miner Res</i>. 2003;18(5):913-918. doi:10.1359/jbmr.2003.18.5.913<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/12733732/pubmed" id="12733732" target="_blank">12733732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12378366">
<a name="12378366"></a>van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. <i>Osteoporos Int</i>. 2002;13(10):777-787. doi:10.1007/s001980200108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/12378366/pubmed" id="12378366" target="_blank">12378366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27940460">
<a name="27940460"></a>Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. <i>Clin J Am Soc Nephrol.</i> 2017;12(2):332-345. doi: 10.2215/CJN.05000516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/27940460/pubmed" id="27940460" target="_blank">27940460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22658245">
<a name="22658245"></a>Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. <i>Am J Cardiol</i>. 2012;110(6):823-825. doi:10.1016/j.amjcard.2012.04.062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22658245/pubmed" id="22658245" target="_blank">22658245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wallace.2020">
<a name="Wallace.2020"></a>Wallace DJ. Overview of the management and prognosis of systemic lupus erythematosus in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28836444">
<a name="28836444"></a>Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. <i>Ann Pharmacother</i>. 2018;52(1):86-90. doi:10.1177/1060028017728297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/28836444/pubmed" id="28836444" target="_blank">28836444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17036562">
<a name="17036562"></a>Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. <i>Mayo Clin Proc</i>. 2006;81(10):1361-1367. doi:10.4065/81.10.1361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17036562/pubmed" id="17036562" target="_blank">17036562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15545676">
<a name="15545676"></a>Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. <i>Ann Intern Med</i>. 2004;141(10):764-770. doi:10.7326/0003-4819-141-10-200411160-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/15545676/pubmed" id="15545676" target="_blank">15545676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22833532">
<a name="22833532"></a>Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2013;65(3):353-361. doi:10.1002/acr.21812<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/22833532/pubmed" id="22833532" target="_blank">22833532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Winpred.1">
<a name="Winpred.1"></a>Winpred (prednisone) [product monograph]. Vaughan, Ontario, Canada: AA Pharma; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23137579">
<a name="23137579"></a>Winthrop KL. Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. <i>Rheum Dis Clin North Am</i>. 2012;38(4):727-745. doi:10.1016/j.rdc.2012.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/23137579/pubmed" id="23137579" target="_blank">23137579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2020">
<a name="WHO.2020"></a>World Health Organization. Corticosteroids for COVID-19: living guidance. 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. Updated September 2, 2020. Accessed December 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8538233">
<a name="8538233"></a>Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. <i>Mayo Clin Proc</i>. 1996;71(1):5-13. doi:10.4065/71.1.5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/8538233/pubmed" id="8538233" target="_blank">8538233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19011472">
<a name="19011472"></a>Yildirim ZK, Büyükavci M, Eren S, Orbak Z, Sahin A, Karakelleoğlu C. Late side effects of high-dose steroid therapy on skeletal system in children with idiopathic thrombocytopenic purpura. <i>J Pediatr Hematol Oncol</i>. 2008;30(10):749-753. doi:10.1097/MPH.0b013e318180bbc9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/19011472/pubmed" id="19011472" target="_blank">19011472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29184808">
<a name="29184808"></a>Younes AK, Younes NK. Recovery of steroid induced adrenal insufficiency. <i>Transl Pediatr</i>. 2017;6(4):269-273. doi:10.21037/tp.2017.10.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/29184808/pubmed" id="29184808" target="_blank">29184808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26611557">
<a name="26611557"></a>Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. <i>Rheum Dis Clin North Am</i>. 2016;42(1):157-x. doi:10.1016/j.rdc.2015.08.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/26611557/pubmed" id="26611557" target="_blank">26611557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25271314">
<a name="25271314"></a>Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. <i>Haematologica</i>. 2014;99(10):1547-1554. doi: 10.3324/haematol.2014.114561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/25271314/pubmed" id="25271314" target="_blank">25271314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeiser.2022">
<a name="Zeiser.2022"></a>Zeiser, R. Treatment of acute graft-versus-host disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prednisone-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zuraw.2021">
<a name="Zuraw.2021"></a>Zuraw B. An overview of angioedema: Clinical features, diagnosis, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 16, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9809 Version 788.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
